WO1999036422A1 - Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme - Google Patents
Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme Download PDFInfo
- Publication number
- WO1999036422A1 WO1999036422A1 PCT/US1999/000810 US9900810W WO9936422A1 WO 1999036422 A1 WO1999036422 A1 WO 1999036422A1 US 9900810 W US9900810 W US 9900810W WO 9936422 A1 WO9936422 A1 WO 9936422A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- integer
- nad synthetase
- synthetase enzyme
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 673
- 108030003379 NAD(+) synthases Proteins 0.000 title claims abstract description 220
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 159
- 238000000034 method Methods 0.000 title claims abstract description 129
- 239000003112 inhibitor Substances 0.000 title claims abstract description 70
- 238000012216 screening Methods 0.000 title claims abstract description 26
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 20
- 230000000813 microbial effect Effects 0.000 title claims abstract description 11
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 8
- -1 alknyl Chemical group 0.000 claims description 90
- 239000002532 enzyme inhibitor Substances 0.000 claims description 89
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 84
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 75
- 241000894006 Bacteria Species 0.000 claims description 65
- 239000012634 fragment Substances 0.000 claims description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 49
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 49
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 37
- 238000012360 testing method Methods 0.000 claims description 37
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 36
- 230000002401 inhibitory effect Effects 0.000 claims description 30
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 28
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 28
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 27
- 239000000463 material Substances 0.000 claims description 27
- 230000003197 catalytic effect Effects 0.000 claims description 25
- 238000004519 manufacturing process Methods 0.000 claims description 25
- 102000004190 Enzymes Human genes 0.000 claims description 24
- 108090000790 Enzymes Proteins 0.000 claims description 24
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 16
- 125000001931 aliphatic group Chemical group 0.000 claims description 16
- 239000003242 anti bacterial agent Substances 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 15
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 150000001448 anilines Chemical class 0.000 claims description 14
- 238000003556 assay Methods 0.000 claims description 14
- AOGQPLXWSUTHQB-UHFFFAOYSA-N hexyl acetate Chemical compound CCCCCCOC(C)=O AOGQPLXWSUTHQB-UHFFFAOYSA-N 0.000 claims description 14
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- 230000000844 anti-bacterial effect Effects 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 235000001968 nicotinic acid Nutrition 0.000 claims description 13
- 239000011664 nicotinic acid Substances 0.000 claims description 13
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 claims description 12
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 12
- 230000000845 anti-microbial effect Effects 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 12
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 150000003384 small molecules Chemical class 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 150000001412 amines Chemical class 0.000 claims description 11
- 238000006555 catalytic reaction Methods 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 230000003115 biocidal effect Effects 0.000 claims description 10
- 238000005859 coupling reaction Methods 0.000 claims description 10
- 125000004122 cyclic group Chemical group 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 239000013078 crystal Substances 0.000 claims description 9
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 239000000645 desinfectant Substances 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- JJSQUEBGFNRLKO-UHFFFAOYSA-N 1h-indol-1-ium;methanesulfonate Chemical compound CS(O)(=O)=O.C1=CC=C2NC=CC2=C1 JJSQUEBGFNRLKO-UHFFFAOYSA-N 0.000 claims description 8
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 8
- 150000002576 ketones Chemical class 0.000 claims description 8
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 125000005750 substituted cyclic group Chemical group 0.000 claims description 8
- 230000002152 alkylating effect Effects 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 7
- GBVAGZMJJSANDQ-UHFFFAOYSA-N benzyl 1h-indole-2-carboxylate Chemical compound C=1C2=CC=CC=C2NC=1C(=O)OCC1=CC=CC=C1 GBVAGZMJJSANDQ-UHFFFAOYSA-N 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- NQPIEWBAWBFGOB-UHFFFAOYSA-N methyl 1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)OC)=CC2=C1 NQPIEWBAWBFGOB-UHFFFAOYSA-N 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 238000007363 ring formation reaction Methods 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 241000192125 Firmicutes Species 0.000 claims description 6
- 150000004982 aromatic amines Chemical class 0.000 claims description 6
- 125000002619 bicyclic group Chemical group 0.000 claims description 6
- GZBPPGUSWAMPLL-UHFFFAOYSA-N carbamimidoyl-(N-nitrocarbamohydrazonoyl)carbamic acid Chemical compound C(=N)(N)N(C(=NN)N[N+](=O)[O-])C(=O)O GZBPPGUSWAMPLL-UHFFFAOYSA-N 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 230000002147 killing effect Effects 0.000 claims description 6
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 6
- 229960003512 nicotinic acid Drugs 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 6
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- RVYGVBZGSFLJKH-UHFFFAOYSA-N hexyl pyridine-3-carboxylate Chemical compound CCCCCCOC(=O)C1=CC=CN=C1 RVYGVBZGSFLJKH-UHFFFAOYSA-N 0.000 claims description 5
- 229940051295 hexylnicotinate Drugs 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- IMSPZLCTPSXORJ-UHFFFAOYSA-N 6-bromohexyl acetate Chemical compound CC(=O)OCCCCCCBr IMSPZLCTPSXORJ-UHFFFAOYSA-N 0.000 claims description 4
- 206010034133 Pathogen resistance Diseases 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 230000000249 desinfective effect Effects 0.000 claims description 4
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims description 4
- 230000003449 preventive effect Effects 0.000 claims description 4
- SGVDDCSUJBVGIG-UHFFFAOYSA-N 1h-indole;trifluoromethanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)F.C1=CC=C2NC=CC2=C1 SGVDDCSUJBVGIG-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 150000008064 anhydrides Chemical class 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 230000003301 hydrolyzing effect Effects 0.000 claims description 3
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052727 yttrium Inorganic materials 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 57
- 239000000243 solution Substances 0.000 description 47
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 45
- 125000005647 linker group Chemical group 0.000 description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 40
- 238000006243 chemical reaction Methods 0.000 description 29
- 239000000203 mixture Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 230000005764 inhibitory process Effects 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 229910001868 water Inorganic materials 0.000 description 20
- 0 CC*(C*(C)C/C1=C\C=C\C(\C(O*I)=O)=C/CC1)*(C=C1)c2c1cc(C)cc2 Chemical compound CC*(C*(C)C/C1=C\C=C\C(\C(O*I)=O)=C/CC1)*(C=C1)c2c1cc(C)cc2 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- SENPVEZBRZQVST-HISDBWNOSA-N deamido-NAD zwitterion Chemical compound [N+]1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@@H]([C@@H]2O)O)N2C=3N=CN=C(C=3N=C2)N)=CC=CC(C(O)=O)=C1 SENPVEZBRZQVST-HISDBWNOSA-N 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 15
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 14
- 235000014469 Bacillus subtilis Nutrition 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 13
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 12
- 239000004599 antimicrobial Substances 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 229950006238 nadide Drugs 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000539 dimer Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000013537 high throughput screening Methods 0.000 description 9
- 150000002611 lead compounds Chemical class 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 244000063299 Bacillus subtilis Species 0.000 description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 6
- 239000007996 HEPPS buffer Substances 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 108010059993 Vancomycin Proteins 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000009510 drug design Methods 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 229960003165 vancomycin Drugs 0.000 description 5
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 5
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241001646716 Escherichia coli K-12 Species 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- YWCASUPWYFFUHE-UHFFFAOYSA-N bis(3-methylsulfonyloxypropyl)azanium;chloride Chemical compound [Cl-].CS(=O)(=O)OCCC[NH2+]CCCOS(C)(=O)=O YWCASUPWYFFUHE-UHFFFAOYSA-N 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000001952 enzyme assay Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000009931 harmful effect Effects 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- 201000008827 tuberculosis Diseases 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000010626 work up procedure Methods 0.000 description 4
- HEGSGKPQLMEBJL-RQICVUQASA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-octoxyoxane-3,4,5-triol Chemical compound CCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RQICVUQASA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000002424 x-ray crystallography Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 101150076489 B gene Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102100025698 Cytosolic carboxypeptidase 4 Human genes 0.000 description 2
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 241000283283 Orcinus orca Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 101100149312 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SER1 gene Proteins 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000405383 Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 2
- 241000680505 Streptococcus pneumoniae WU2 Species 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000010936 aqueous wash Methods 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000013100 final test Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002922 simulated annealing Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960000707 tobramycin Drugs 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HMPQYNDIVXKOOM-UHFFFAOYSA-N 1h-indole;sodium Chemical compound [Na].C1=CC=C2NC=CC2=C1 HMPQYNDIVXKOOM-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000004810 2-methylpropylene group Chemical group [H]C([H])([H])C([H])(C([H])([H])[*:2])C([H])([H])[*:1] 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- BCVZTEPXSGWBAY-UHFFFAOYSA-N 5-bromohexyl acetate Chemical compound CC(Br)CCCCOC(C)=O BCVZTEPXSGWBAY-UHFFFAOYSA-N 0.000 description 1
- 241000186041 Actinomyces israelii Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000053640 Argininosuccinate synthases Human genes 0.000 description 1
- 108700024106 Argininosuccinate synthases Proteins 0.000 description 1
- 102100023927 Asparagine synthetase [glutamine-hydrolyzing] Human genes 0.000 description 1
- 108010070255 Aspartate-ammonia ligase Proteins 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000180135 Borrelia recurrentis Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000722910 Burkholderia mallei Species 0.000 description 1
- 241000316922 Caldicoprobacter faecalis Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- JJLJMEJHUUYSSY-UHFFFAOYSA-L Copper hydroxide Chemical compound [OH-].[OH-].[Cu+2] JJLJMEJHUUYSSY-UHFFFAOYSA-L 0.000 description 1
- 239000005750 Copper hydroxide Substances 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101000932590 Homo sapiens Cytosolic carboxypeptidase 4 Proteins 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000244587 Leucanthemopsis pallida Species 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- 101001033003 Mus musculus Granzyme F Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- WWNNZCOKKKDOPX-UHFFFAOYSA-O N-methylnicotinic acid Chemical compound C[N+]1=CC=CC(C(O)=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-O 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 208000006731 Salmonella Food Poisoning Diseases 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241001478878 Streptobacillus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000606834 [Haemophilus] ducreyi Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- AMKORRFMCUEAGG-UHFFFAOYSA-N acetic acid hypobromous acid Chemical compound OBr.CC(O)=O AMKORRFMCUEAGG-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ZKPHYUDUHAIMCK-UHFFFAOYSA-N ambtos828244 Chemical compound C12=CC=CC(=O)N2CC2CN(CC(=O)OC)CC1C2 ZKPHYUDUHAIMCK-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WGHQMEJYSKKAGF-UHFFFAOYSA-N benzyl quinoline-3-carboxylate Chemical compound C=1N=C2C=CC=CC2=CC=1C(=O)OCC1=CC=CC=C1 WGHQMEJYSKKAGF-UHFFFAOYSA-N 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000009614 chemical analysis method Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 229910001956 copper hydroxide Inorganic materials 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000011548 crystallization buffer Substances 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- GLYLMXARZJNUEY-UHFFFAOYSA-N dichloromethane;methanol;hydrate Chemical compound O.OC.ClCCl GLYLMXARZJNUEY-UHFFFAOYSA-N 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960004887 ferric hydroxide Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 1
- 229910021506 iron(II) hydroxide Inorganic materials 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 238000002898 library design Methods 0.000 description 1
- 125000002463 lignoceryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012900 molecular simulation Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
- A01N43/38—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
- A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Definitions
- the present invention pertains to antibacterial and antimicrobial agents.
- the present invention provides methods of synthesizing and screening compounds that are bacterial nicotinamide adenine dinucleotide (NAD) synthetase enzyme inhibitors.
- NAD bacterial nicotinamide adenine dinucleotide
- the present invention also provides novel compounds that inhibit bacterial NAD synthetase enzyme.
- the invention also provides libraries of compounds that comprise bacterial NAD synthetase enzyme inhibitors.
- the present invention provides compounds that exhibit therapeutic activity as antibacterial agents, antimicrobial agents and broad spectrum antibiotics.
- the invention provides methods of treating a mammal with bacterial NAD synthetase enzyme inhibitor compounds.
- the present invention also provides novel disinfecting agents. ⁇ . Background of the Invention:
- Drug-resistant infectious bacteria that is, bacteria that are not killed or inhibited by existing antibacterial and antimicrobial compounds, have become an alarmingly serious worldwide health problem. (E. Ed. Rubenstein, Science, 264, 360 (1994)). In fact, a number of bacterial infections may soon be untreatable unless alternative drug treatments are identified.
- Streptococcus pneumoniae causes thousands of cases of meningitis and pneumonia, as well as 7 million cases of ear infection in the United States each year. Currently, about 30 percent of S. pneumoniae isolates are resistant to penicillin, the primary drug used to treat this infection. Many penicillin-resistant strains are also resistant to other antimicrobial or antibacterial drugs.
- MDR-TB multi-drug resistant tuberculosis
- antibacterial agents that inhibit or block essential bacterial metabolic mechanisms, to result in bacterial death or deactivation, without also effecting the essential metabolic activities of a mammalian host. That is, it would be desirable to develop antibacterial agents that preferentially attack bacteria and other microbes and kill or deactivate the harmful organism without causing any attendant undesirable side effects in a human or animal patient. It would also be desirable to develop methods of rapidly screening potential new antimicrobial and antibacterial agents. It would also be desirable to develop novel disinfecting agents.
- the invention provides a NAD synthetase inhibitor compound of the formula:
- the invention provides a bacterial NAD synthetase enzyme inhibitor compound, having Structure 2:
- R t - R 7 each, independently, is an H, an unsubstituted or a substituted cyclic or aliphatic group, a branched or an unbranched group, wherein the linker is a cyclic or aliphatic, branched or an unbranched alkyl, alkenyl, or an alkynyl group and wherein the linker may also contain heteroatoms.
- the invention provides a bacterial NAD synthetase enzyme inhibitor compound, having Structure 4:
- X is a C, N, O or S within a monocyclic or bicyclic moiety
- a and B represent the respective sites of attachment for the linker
- n is an integer of from 1 to 12
- R1-R7 each, independently, is an H, an unsubstituted or a substituted cyclic group, or an aliphatic group, or a branched or an unbranched group
- the linker is a saturated or unsaturated cyclic group or an aliphatic branched or unbranched alkyl, alkenyl or alkynyl group, and wherein the linker may also contain heteroatoms.
- the invention provides a method of treating or preventing a microbial infection in a mammal comprising administering to the mammal a treatment effective or treatment preventive amount of a bacterial NAD synthetase enzyme inhibitor compound. Still further, a method is provided of killing a prokaryote with an amount of prokaryotic NAD synthetase enzyme inhibitor to reduce of eliminate the production of NAD whereby the prokaryote is killed. Moreover, a method is provided of decreasing prokaryotic growth, comprising contacting the prokaryote with an amount of a prokaryotic NAD synthetase enzyme inhibitor effective to reduce or eliminate the production of NAD whereby prokaryotic growth is decreased.
- the invention provides a method of disinfecting a material contaminated by a microbe, comprising contacting a contaminated material with a bacterial NAD synthetase enzyme inhibitor compound in an amount sufficient to kill or deactivate the microbe.
- the invention provides a method of making a bacterial NAD synthetase inhibitor compound comprising the steps of: a. alkylating 5-nitroindole with 6- bromohexyl acetate to form a 6-[N-(5-nitroindolyl)] hexyl acetate; b. hydrolyzing the 6- [N-(5-nitroindolyl)] hexyl acetate to form ⁇ 5-/N-(5-nitroindolyl)]hexan-l-ol; c.
- the invention provides a method of making a bacterial NAD synthetase inhibitor compound comprising the steps of: a. alkylating 5-nitroindole with bromoalkyl acetate wherein the indole alkyl acetate is converted to indole alkyl alcohol; b. reacting the indole alkyl alcohol with the appropriate reagent to form an indole alkyl ester; and c. N- Moreover, the invention provides a method of making a bacterial NAD synthetase inhibitor compound comprising the steps of: a.
- indole carboxylic acid with the appropriate reagent to provide an indole carboxylate methyl ester or an indole benzyl carboxylate ester
- the invention provides a method of making a bacterial NAD synthetase inhibitor compound comprising the steps of: a. brominating an aniline with N- bromosuccinimide to form a 2-bromo-R 1 -substituted-aniline or a 2-bromo-R 2 -substituted- aniline; b. reacting the 2-bromo-R 1 -substituted-aniline or the 2-bromo-R 2 -substituted- aniline using a Heck coupling reaction to form an alkyne-substituted aniline; c.
- the invention provides a method of making a bacterial NAD synthetase inhibitor compound comprising the steps of: a. brominating an aniline with N- bromosuccinimide to form a 2-bromo-R 1 -substituted-aniline or a 2-bromo-R 2 -substituted- aniline; b. reacting the 2-bromo-R 1 -substituted-aniline or a 2-bromo-R 2 -substituted-aniline using a Heck coupling reaction to form an alkyne-substituted aniline; c.
- the invention provides a method of generating a library comprising at least one bacterial NAD synthetase enzyme inhibitor compound comprising the steps of: a. obtaining the crystal structure of a bacterial NAD synthetase enzyme; b.
- identifying one or more sites of catalytic activity on the NAD synthetase enzyme c. identifying the chemical structure of the catalytic sites on the NAD synthetase enzyme; d. selecting one or more active molecules that will demonstrate affinity for at least one of the catalytic sites on the NAD synthetase enzyme; f. synthesizing one or more dimeric compounds comprised of at least one active molecule wherein the active molecule compound are joined by means of n linker compounds and wherein n is an integer of from 1 to 12, and g. screening the one or more compounds for NAD synthetase inhibitor activity.
- a method for the in vitro screening a compound for bacterial NAD synthetase enzyme inhibitory activity comprising the steps of: a. preparing a bacterial NAD synthetase enzyme solution from pure bacterial NAD synthetase enzyme mixed with a suitable buffer; b. contacting the bacterial NAD synthetase enzyme solution with a test compound; and c. measuring the rate of the enzyme-catalyzed reaction between the NAD synthetase enzyme and the test compound, wherein the rate of the enzyme catalyzed reaction comprises a measure of bacterial NAD synthetase enzyme inhibitory activity.
- Ranges may be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about,” it will be understood that the particular value forms another embodiment.
- o-methylbenzoic acid is represented.
- alkyl refers to a branched or unbranched saturated hydrocarbon group of 1 to 24 carbon atoms, such as methyl, ethyl, w-propyl, isopropyl, H-butyl, isobutyl, t-butyl, octyl, decyl, tetradecyl, hexadecyl, eicosyl, tetracosyl and the like.
- cycloalkyl intends a cyclic alkyl group of from three to eight, preferably five or six carbon atoms.
- alkoxy intends an alkyl group bound through a single, terminal ether linkage; that is, an “alkoxy” group may be defined as -OR where R is alkyl as defined above.
- a "lower alkoxy” group intends an alkoxy group containing from one to six, more preferably from one to four, carbon atoms.
- alkylene refers to a difunctional saturated branched or unbranched hydrocarbon chain containing from 1 to 24 carbon atoms, and includes, for example, methylene (-CH2-), ethylene (-CH2-CH2-), propylene (-CH2-CH2-CH2-), 2-methylpropylene [-CH2-CH(CH3)-CH2-], hexylene [-(CH2)6-] and the like.
- cycloalkylene refers to a cyclic alkylene group, typically a 5- or 6-membered ring.
- alkene intends a mono-unsaturated or di-unsaturated hydrocarbon group of 2 to 24 carbon atoms.
- alkynyl refers to a branched or unbranched unsaturated hydrocarbon group of 1 to 24 carbon atoms wherein the group has at least one triple bond.
- cyclic intends a structure that is characterized by one or more closed rings.
- the cyclic compounds discussed herein may be saturated or unsaturated and may be heterocyclic.
- heterocyclic it is meant a closed- ring structure, preferably of 5 or 6 members, in which one or more atoms in the ring is an element other than carbon, for example, sulfur, nitrogen, etc.
- bicyclic intends a structure with two closed rings. As further used herein, the two rings in a bicyclic structure can be the same or different. Either of the rings in a bicyclic structure may be heterocyclic.
- an effective amount of a compound as provided herein is meant a sufficient amount of the compound to provide the desired treatment or preventive effect.
- the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease that is being treated, the particular compound used, its mode of administration, and the like. Thus, it is not possible to specify an exact "effective amount.” However, an appropriate effective amount may be determined by one of ordinary skill in the art using only routine experimentation. It is preferred that the effective amount be essentially non- toxic to the subject, but it is contemplated that some toxicity will be acceptable in some circumstances where higher dosages are required.
- pharmaceutically acceptable carrier a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with the compounds of the invention without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.
- NAD synthetase enzyme is defined as the enzyme that catalyzes the final reaction in the biosynthesis of NAD, namely, the transformation of NaAD into NAD.
- catalytic sites are defined as those portions of the NAD synthetase enzyme that bind to substrates, and cofactors, including nictonic acid dinucleotide (NaAD), NAD, adenosine triphosphate (ATP), adenosine monophosphate (AMP), pyrophosphate, magnesium and ammonia in bacteria or microbes.
- receptor site or "receptor subsite” relates to those portions of the bacterial NAD synthetase enzyme in which the bacterial NAD synthetase enzyme inhibitors disclosed herein are believed to bind.
- the terms "catalytic site,” “receptor site” and “receptor subsite” may be used interchangeably.
- the terms "library” and "library of compounds” denote an intentionally created collection of differing compounds which can be prepared by the synthetic means provided herein or generated otherwise using synthetic methods utilized in the art.
- the library can be screened for biological activity in any variety of methods, such as those disclosed below herein, as well as other methods useful for assessing the biological activity of chemical compounds.
- the means utilized to generate the libraries herein comprise generally combinatorial chemical methods such as those described in Gallop, et al, "Applications of Combinatorial Techniques to Drug Discovery," “Part 1 Background and Peptide Combinatorial Libraries,” and “Part 2: Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions," J. Med. Chem., Vol. 37(1994) pp.
- the terms “combinatorial chemistry” or “combinatorial methods” are defined as the systematic and repetitive, covalent connection of a set of different “building blocks” of varying structure, such as the active molecules disclosed herein, to provide a large array of diverse molecular entities. As contemplated herein, the large array of diverse molecular entities together form the libraries of compounds of the invention.
- antibacterial compound denotes a material that kills or deactivates bacteria or microbes so as to reduce or eliminate the harmful effects of the bacteria on a subject or in a system. Such materials are also known in the art as “bacteriostatic agents” or “bateriocidal agents.” The bacteria so effected can be gram positive, gram negative or a combination thereof.
- antimicrobial compound and “broad spectrum antibiotic” denote a material that kills or deactivates a wide variety of microbes, including, but not limited to, one of more of, gram positive or gram negative bacteria, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, Enterococcus, anaerobic Streptococcus, Pneumococcus, Gonococcus, Meningococcus, Mima, Bacillus anthracis, C. diphtheriae, List, monocytogenes, Streptobacillus monohiliformis, Erysipelothrix insidiosa, E. coli, A.
- aerogenes A. faecalis, Proteus mirabilis, Pseudomonas aeruginosa, K. pneumoniae, Salmonella, Shigella, H. influenzae, H. ducreyi, Brucella, Past, pestis, Past, tularensis, Past, multocida, V. comma, Actinobacillus mallei, Pseud, pseudomallei, CI. tetani, Bacteroides, Fusobacterium fusiforme, M. tuberculosis, atypical mycobacteria, Actinomyces israelii, Nocardia, T. pallidum, T. pernue, Borrelia recurrentis, Peptospira, Rickettsia, and Mycoplasma pneumoniae.
- novel compounds have been identified that inhibit bacterial NAD synthetase enzymatic activity. Such activity translates into effectiveness as bacteriocidal agents, as well as effectiveness a broad spectrum antibiotic materials.
- Novel compounds have been developed that inhibit a previously unrecognized target in prokaryotic organisms, such as bacteria, to block essential biological function and thereby cause bacterial death or deactivation of bacteria or other microbes.
- the invention herein has identified an enzyme found in both gram positive and gram negative bacteria, NAD synthetase enzyme, which can be utilized as a target for drug design to provide protection from and/or treatment for bacterial and other microbial infections.
- NAD synthetase enzyme catalyzes the final step in the biosynthesis of nicotinamide adenine dinucleotide (NAD).
- Bacterial NAD synthetase is an ammonia- dependent amidotransferase belonging to a family of "N-type" ATP pyrophosphatases; this family also includes asparagine synthetase and argininosuccinate synthetase.
- NAD synthetase enzyme catalyzes the last step in both the de novo and salvage pathways for NAD + biosynthesis, which involves the transfer of ammonia to the carboxylate of nicotinic acid adenine dinucleotide (NaAD) in the presence of ATP and Mg +2 .
- NaAD nicotinic acid adenine dinucleotide
- prokaryotic NAD synthetase in bacteria utilizes ammonia as the sole nitrogen source.
- the invention has identified marked differences in the structures of eukaryotic and prokaryotic forms of the NAD synthetase enzyme.
- B. subtilis NAD synthetase enzyme which in the invention has been crystallized and used in the drug design methodologies herein, is a dimeric material with molecular weight around 60,500.
- the eukaryotic form of NAD synthetase found in yeast and mammals is multimeric and has a molecular weight of at least 10 times larger.
- the invention herein provides novel compounds that can be utilized as antibacterial and antimicrobial agents that specifically target the prokaryotic NAD synthetase enzyme without also effecting a mammalian host.
- the invention herein it has been found that by specifically inhibiting bacterial NAD synthetase enzymatic activity, bacteria can be deprived of the energy necessary to thrive and replicate.
- antibacterial and antimicrobial drugs have been developed that preferentially attack the bacteria to kill or deactivate it so as to reduce or eliminate its harmful properties, without appreciably affecting mammalian NAD synthetase enzymatic activity at the same dosage.
- novel methods are provided that allow the rapid screening of compounds for bacterial NAD synthetase enzyme inhibitory activity.
- the invention provides methods of treating microbial infections in a subject.
- FIGURE 2 CATALYTIC SITES IN BACTERIAL NAD SYNTHETASE ENZYME
- FIG. 4 illustrates via cartoon a bacterial NAD synthetase enzyme in which the catalytic sites are blocked by an example of a compound of the present invention.
- FIGURE 4 BACTERIAL NAD SYNTHETASE ENZYME WITH BLOCKED CATALYTIC/RECEPTOR SITES
- spore-forming bacteria will be unable to undergo germination and outgrowth, and the essential cellular respiratory functions of the vegetative bacteria will be halted, thereby causing cellular death or deactivation, e.g., gram positive and gram negative bacteria and other microbes will be killed or prevented from undergoing growth.
- the invention has found that compounds that exhibit inhibitory activity against the bacterial NAD synthetase enzyme will also exhibit therapeutic activity as antibacterial and antimicrobial compounds, as well as broad spectrum antibiotic materials.
- the active molecules are comprised of substituent groups as hereinafter disclosed that will bind with at least one of the receptor sites in bacterial NAD synthetase enzyme.
- one or more active molecules are tethered together to form a dimeric molecule that is capable of inhibiting the bacterial NAD synthetase enzyme.
- selective affinity means that the active molecule shows enhanced tendency to bind with one subsite with the receptor in the bacterial NAD synthetase enzyme because of a chemical complementarity between the receptor subsite and the active molecule.
- a tethered dimer compound is illustrated in Scheme 2 below.
- a dimeric inhibitor compound will bind with, for example, the sites of catalytic activity on the bacterial NAD synthetase enzyme, thereby preventing the production of NAD/NADH by the bacteria.
- a software program can be utilized which facilitates the prediction of the binding affinities of molecules to proteins so as to allow identification of commercially available small molecules with the ability to bind to at least one receptor subsite in the bacterial NAD synthetase enzyme.
- An example of one such computer program is DOCK, available from the Department of Pharmaceutical Chemistry at the University of California, San Francisco. DOCK evaluates the chemical and geometric complementarity between a small molecule and a macromolecular binding site.
- DOCK evaluates the chemical and geometric complementarity between a small molecule and a macromolecular binding site.
- such a program would be useless in the design of a bacterial NAD synthetase enzyme inhibitor in the absence of complete information regarding the enzyme's structure and the chemical makeup of the receptor sites, identified and disclosed fully for the first time herein.
- the crystal structure of one type of bacterial NAD synthetase enzyme e.g., B. subtilis has been for the first time identified fully.
- the x-ray crystal structure of NAD synthetase enzyme from B. subtilis had been reported in the literature. This was accomplished in free form and in complex with ATP and Mg +2 at 2.6 and 2.0 A, respectively.
- This structure contained the hydrolyzed form of ATP, namely AMP and Ppi, in the ATP binding site and ATP was present in the NaAD binding site.
- the prior art was not able to obtain the structure of the enzyme complex containing NaAD due to technical problems that precluded full identification. Without the structure of the enzyme complex containing NaAD, the structure-based drug design targeted to NAD synthetase enzyme of the present invention could not be developed.
- the invention utilizes two approaches reported in the literature (for other biological targets) to help identify lead compounds.
- DOCK I.D. Kunz et al., J. Mol. Biol., 161, 269-288 (1982)
- DOCK was utilized to search the Available Chemicals Directory database and computationally score the relative binding affinities for each structure. Based on these results and structural information regarding substrate binding, commercially available compounds were selected for purchase and subsequent enzyme kinetics evaluation.
- database searching strategies in drug discovery are now commonly used by those of skill in the art of drug design. (D.T. Manallack, Drug Discovery Today, 1, 231-238 (1996)).
- Examples from the top scoring small molecules as determined by, for example, DOCK are preferably pre-screened using in vitro enzyme assays as further described herein.
- the preferred screening method utilized should allow the rapid screening of large numbers of compounds for inhibitory activity.
- the small molecule inhibitor candidate for each site that is most promising as an active molecule, as identified by DOCK (or other programs known to one of skill in the art) and the prescreening method herein, or that were designed based upon the substrate protein complex structure were synthesized according to the methods disclosed herein below.
- the active molecules are chemically tethered to one another by means of a linker compound.
- the linker comprises one or more CH 2 or other groups, using a variety of tether lengths, preferably 1 to 12 nonhydrogen atoms, more preferably 3 to 10 nonhydrogen atoms, further more preferably 5 to 9 nonhydrogen atoms and, still more preferably, 6 to 9 nonhydrogen atoms.
- novel compounds with preferred structures determined from the methods described above are synthesized by means of rapid, solution phase parallel synthesis of the tethered dimers compounds in a combinatorial fashion.
- One of skill in the art will recognize such techniques.
- a novel synthetic strategy was developed to allow variation in the length of the linking group through which the active molecules are joined. These synthetic strategies are set forth herein as Schemes 3 through 6 and in Examples 1 through 4 below.
- Use of the preferred method of variable linkage greatly increases the number of different tethered dimeric compounds that can be produced from a single pair of the same or different active molecules.
- the active molecules specifically disclosed herein may be used, as well as any pharmaceutically acceptable salts thereof.
- pharmaceutically acceptable salts of the compounds set out herein below are also contemplated for use in this invention. Such salts are prepared by treating the free acid with an appropriate amount of a pharmaceutically acceptable base.
- Representative pharmaceutically acceptable bases are ammonium hydroxide, sodium hydroxide, potassium hydroxide, lithium hydroxide, calcium hydroxide, magnesium hydroxide, ferrous hydroxide, zinc hydroxide, copper hydroxide, aluminum hydroxide, ferric hydroxide, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, lysine, arginine, histidine, and the like.
- the reaction is conducted in water, alone or in combination with an inert, water-miscible organic solvent, at a temperature of from about 0°C to about 100°C, preferably at room temperature.
- the molar ratio of compounds of structural formula (I) to base used are chosen to provide the ratio desired for any particular salts.
- the ammonium salts of the free acid starting material-a particular preferred embodiment-the starting material can be treated with approximately one equivalent of pharmaceutically acceptable base to yield a neutral salt.
- calcium salts are prepared, approximately one-half a molar equivalent of base is used to yield a neutral salt, while for aluminum salts, approximately one-third a molar equivalent of base will be used.
- the invention provides a method of making a bacterial NAD synthetase inhibitor compound comprising the steps of:
- Schemes 4-6 Examples of additional preferred synthetic procedures utilized for preparing the library of the present invention are provided in Schemes 4-6.
- Schemes 4-6 it is preferable to utilize combinatorial methods of synthesis using, for example, parallel solution phase synthesis techniques.
- combinatorial methods of synthesis using, for example, parallel solution phase synthesis techniques.
- One of skill in the art will readily recognize the manner in which the synthetic pathways disclosed below may be varied without departing from the novel and unobvious aspects of the invention.
- the invention provides a method of synthesizing a NAD synthetase inhibitor compound from the route set out in Scheme 4 above, comprising the steps of: a. alkylating 5-nitroindole with bromoalkyl acetate wherein the indole alkyl acetate is converted to indole alkyl alcohol; b. reacting the indole alkyl alcohol with the appropriate reagent to form an indole alkyl ester; and c. N-methylating the indole alkyl ester.
- the invention provides a method of making a NAD synthetase inhibitor compound from the route set out in Scheme 4 above comprising the steps of: a. alkylating 5-nitroindole with bromoalkyl acetate wherein the indole alkyl acetate is converted to indole alkyl alcohol; b. reacting the indole alkyl alcohol with the appropriate reagent to form an indole alkyl ester; and c. reacting the indole alkyl alcohol with mesyl chloride followed by reaction with an amine to generate an ammonium product.
- the invention provides a method of making a NAD synthetase inhibitor from the route set out in Scheme 5 above, comprising the steps of: a. reacting indole carboxylic acid with the appropriate reagent to provide an indole carboxylate methyl ester or an indole benzyl carboxylate ester; b. N-alkylating the indole carboxylate methyl ester or the indole carboxylate benzyl ester with bromoalkyl acetate; c. reacting the material from step b above with the appropriate reagent to form an indolealkyl alcohol; d.
- the invention provides a method of making a NAD synthetase inhibitor from the route set out in Scheme 6 above, comprising the steps of: a. brominating an aniline with N-bromosuccinimide to form a 2-bromo-R 1 - substituted-aniline or a 2-bromo-R 2 -substituted-aniline; b. reacting the 2-bromo-R 1 -substituted- aniline or the 2-bromo-R 2 -substituted- aniline using a Heck coupling reaction to form an alkyne-substituted aniline; c.
- the invention provides a method of making a NAD synthetase inhibitor compound from the route set out in Scheme 6 above, comprising the steps of: a. brominating an aniline with N-bromosuccinimide to form a 2-bromo-R 1 - substituted-aniline or a 2-bromo-R 2 -substituted-aniline; b. reacting the 2-bromo-R 1 -substituted-aniline or a 2-bromo-R 2 -substituted- aniline using a Heck coupling reaction to form an alkyne-substituted aniline; c.
- the invention provides a compound having the general structure of Structure 2:
- n is an integer of from 1 to 12, R; - R 7 each, independently, is an H, an unsubstituted or a substituted cyclic or aliphatic group, a branched or an unbranched group, and wherein the linker is a cyclic or aliphatic, branched or an unbranched alkyl, alkenyl, or an alkynyl group and wherein the linker may also contain heteroatoms.
- heteroatoms it is meant that one or more atoms is an element other than carbon.
- R,-R 7 may also be one of the following groups: an H, alkyl, alkenyl, alknyl, or an aryl.
- R j -R ⁇ may further be a hydroxyl, ketone, nitro, amino, amidino, guanidino, carboxylate, amide, sulfonate, or halogen or the common derivatives of these groups.
- N may also be an integer of from 3 to 10, more preferably 5 to 9 and, still more preferably 6 to 9.
- the tethered active molecule, e.g., in this example denoted "aryl,” moieties may be the same or different.
- the invention provides a compound of Structure 4:
- X is a C, N, O or S within a monocyclic or bicyclic moiety
- a and B represent the respective sites of attachment for the linker
- n is an integer of from 1 to 12
- R j -R y each, independently, is an H, an unsubstituted or a substituted cyclic group, or an aliphatic group, or a branched or an unbranched group
- the linker is a saturated or unsaturated cyclic group or an aliphatic branched or unbranched alkyl, alkenyl or alkynyl group, and wherein the linker may also contain heteroatoms.
- R r R 7 may also be one of the following groups: an H, alkyl, alkenyl, alkynyl, or an aryl group.
- R,-R 7 may also be a hydroxyl, ketone, nitro, amino, amidino, guanidino, carboxylate, amide, sulfonate, or halogen or the common derivatives of these groups.
- One of skill in the art would know what moieties are considered to constitute derivatives of these groups.
- N may also be an integer of from 3 to 10, more preferably 5 to 9 and, still more preferably 6 to 9.
- the invention provides a compound of Structure 6:
- X is C, N, O or S
- Y is C, N, O, S, carboxy, ester, amide, or ketone
- a and B represent the respective sites of attachment for a linker
- n is an integer of from 1 to 12
- R ] -R 7 each, independently, is an H, unsubstituted or substituted cyclic group or an aliphatic group, a branched or an unbranched group
- the linker is a saturated or unsaturated cyclic or aliphatic group, branched or unbranched alkyl, alkenyl, or alkynyl group and wherein the linker may also contain heteroatoms.
- R,-R 7 may also be one of the following groups: an H, alkyl, alkenyl, or alkynyl, or an aryl group. may also be an H, hydroxyl, ketone, nitro, amino, amidino, guanidino, carboxylate, amide, sulfonate, or halogen and the common derivatives of these groups. One of skill in the art would know what moieties are considered to constitute derivatives of these groups. N may also be an integer of from 3 to 10, more preferably 5 to 9 and, still more preferably 6 to 9.
- the invention provides a compound of Structure 8: STRUCTURE 8:
- n is an integer of from 1 to 12
- R is an H, methoxy, benzyloxy, or nitro
- R 2 is 3- pyridyl, N-methyl-3-pyridyl, 3-quinolinyl, N-methyl-3-quinolinyl, 3-
- N may also be an integer of from 3 to 10, more preferably 5 to 9 and, still more preferably 6 to 9.
- the invention provides a compound of Structure 10:
- n is an integer of from 1 to 12
- R is an H, CO 2 H, -OCH 3 , or -OCH 2 Ph
- R 3 is H or CO 2 H
- Y is N-linked pyridine-3-carboxylic acid, N-linked pyridine, N-linked quinoline, or N-linked isoquinoline.
- N may also be an integer of from 3 to 10, more preferably 5 to 9 and, still more preferably 6 to 9.
- the invention provides a compound of Structure 12:
- n is an integer of from 1 to 12
- R] is H, F, or NO 2
- R 2 is H, CH 3 , CF 3 , NO 2 , phenyl, n-butyl, isopropyl, F, phenyloxy, triphenylmethyl, methoxycarbonyl, methoxy, carboxy, acetyl, or benzoyl
- R 3 is H or CF 3
- Y is N-linked pyridine-3 -carboxylic acid, N-linked pyridine, N-linked quinoline, or N-linked isoquinoline.
- N may also be an integer of from 3 to 10, more preferably 5 to 9 and, still more preferably 6 to 9.
- the invention provides a compound of Structure 14:
- n is an integer of from 1 to 12
- R is H, phenyloxy, isopropyl, acetyl, or benzoyl
- R 2 is H or CF 3
- Y is 3-(dimethylamino)phenyl, 3-(trimelthylammonio)phenyl, 4- (dimethylamino)phenyl, 4-(trimethylammonio)phenyl, 2-(phenyl)phenyl, diphenylmethyl, 3-pyridyl, 4-pyridyl, or pyridine-3-methyl.
- N may also be an integer of from 3 to 10, more preferably 5 to 9 and, still more preferably 6 to 9.
- the invention provides a compound of Structure 16:
- R is H or CO 2 CH 3 and n is an integer of from 1 to 4, more preferably 2 to 3, and even more preferably, n is 3.
- the invention provides a compound of Structure 18:
- R is H or CO 2 CH 3 and n is an integer of from 1 to 4, more preferably 2 to 3, and even more preferably, n is 3.
- T designates generally the presence of an anion.
- the type of anion in the compounds of this invention is not critical.
- the anions present in the compounds of this may be comprised of any such moieties known generally to one of skill in the art or that follow from the synthesis methods disclosed herein.
- FIGURE 6 FRAGMENTS UTILIZED IN COMPOUNDS 1-274
- R' is:
- N is an integer of from 1 to 12.
- N may also be from 3 to 10, more preferably 5 to 9 and, still more preferably 6 to 9.
- n may also be an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9.
- R' co ⁇ esponds to a Fragment as previously defined in Figure 6 and n indicates the number of linker groups separating the two tethered active molecule groups in the compound.
- Fragments A - G are set out in Figure 8.
- the group denoted R in A-G of Figure 8 can be a benzyl group, a methyl group or a hydrogen.
- the point of attachment of the linker group to Fragments A-G is at the nitrogen group.
- the compounds of the present invention co ⁇ espond to compounds of Structure 101.
- n is an integer of from 1 to 12, more preferably from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9.
- the point of attachment of the linker group for both Rl and R' is at the respective nitrogen groups of each illustrated fragment.
- R group in Fragments A-G is a benzyl group, a methyl group or a hydrogen.
- the compounds of the present invention may include the Fragments illustrated below in Figure 8.
- FIGURE 8 FRAGMENTS A-G IN COMPOUNDS 25-274
- the compounds of the present invention co ⁇ espond to the structures set out in Structure 102.
- n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9.
- the compounds herein co ⁇ espond to Structure 102, as further set out in Table 102.
- R' co ⁇ esponds to a Fragment as previously defined in Figure 6
- A co ⁇ esponds to a Fragment as previously defined in Figure 8
- n indicates the number of linker groups separating Groups R' and A in the respective compounds.
- Groups I, II, VII, VIII each have a benzyl group and Groups I*, IIP, VII*, VIII* each have a hydrogen, respectively, in the position designated R in Fragment A of Figure 8.
- the compounds of the present invention co ⁇ espond to the structures set out in Structure 104.
- n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9.
- the compounds herein co ⁇ espond to Structure 104, as further set out in Table 104.
- R' co ⁇ esponds to a Fragment as previously defined in Figure 6
- B co ⁇ esponds to a Fragment as previously defined in Figure 8
- n indicates the number of linker groups separating Groups R' and B in the respective compounds.
- Groups I, VII, VIII each have a benzyl group and Groups I*, VII*, NQI* each have a hydrogen, respectively, in the position designated R in Fragment B of Figure 8.
- the compounds of the present invention co ⁇ espond to the structures set out in Structure 106.
- n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9.
- the compounds herein co ⁇ espond to Structure 106, as further set out in Table 106.
- R' co ⁇ esponds to a Fragment as previously defined in Figure 6
- C co ⁇ esponds to a Fragment as previously defined in Figure 8
- n indicates the number of linker groups separating Groups R' and C in the respective compounds.
- Groups I, II, VII, V ⁇ i each have a benzyl group and Groups I*, HI*, VII*, VIII* each have a hydrogen, respectively, in the position designated R in Fragment C of Figure 8.
- the compounds of the present invention co ⁇ espond to the structures set out in Structure 108.
- n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9.
- the compounds herein co ⁇ espond to Structure 108, as further set out in Table 108.
- R' co ⁇ esponds to a Fragment as previously defined in Figure 6
- D co ⁇ esponds to a fragment as previously defined in Figure 8
- n indicates the number of linker groups separating Groups R' and D in the compound.
- Groups I, VII, VIII each have a benzyl group and Groups I*, VII*, VIE* each have a hydrogen, respectively, in the position designated R in Fragment D of Figure 8.
- the compounds of the present invention co ⁇ espond to the structures set out in Structure 110.
- n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9.
- the compounds herein co ⁇ espond to Structure 110, as further set out in Table 110.
- R' co ⁇ esponds to a Fragment as previously defined in Figure 6
- E co ⁇ esponds to a Fragment as previously defined in Figure 8
- n indicates the number of linker groups separating Groups R' and E in the respective compounds.
- Groups I, VII, VIII each have a benzyl group and Groups I*, VII*, VIII* each have a hydrogen, respectively, in the position designated R in Fragment E of Figure 8.
- the compounds of the present invention co ⁇ espond to the structures set out in Structure 112.
- n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9.
- the compounds herein co ⁇ espond to Structure 112, as further set out in Table 112.
- R' co ⁇ esponds to a Fragment as previously defined in Figure 6
- F co ⁇ esponds to a Fragment as previously defined in Figure 8
- n indicates the number of linker groups separating Groups R' and F in the respective compounds.
- Groups I, VII, VIII each have a benzyl group and Groups I*, VE*, VIII* each have a hydrogen, respectively, in the position designated R in Fragment F of Figure 8.
- the compounds of the present invention co ⁇ espond to the structures set out in Structure 114.
- n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9.
- the compounds herein co ⁇ espond to Structure 114, as further set out in Table 114.
- R' co ⁇ esponds to a Fragment as previously defined in Figure 6
- G co ⁇ esponds to a Fragment as previously defined in Figure 8
- n indicates the number of linker groups separating Groups R' and G in the respective compounds.
- Groups I, VE, VIE each have a benzyl group and Groups I*, VE*, VEI* each have a hydrogen, respectively, in the position designated R in Fragment G of Figure 8.
- the compounds of the present invention co ⁇ espond to the structures set out in Structure 116.
- n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9.
- the compounds herein co ⁇ espond to Structure 116, as further set out in Table 116.
- R' co ⁇ esponds to a Fragment as previously defined in Figure 6
- A co ⁇ esponds to a Fragment as previously defined in Figure 8
- n indicates the number of linker groups separating Groups R' and A in the respective compounds.
- Groups I, II each have a methyl group and Groups I*, IE* each have a hydrogen, respectively, in the position designated R in Fragment A of Figure 8.
- the compounds of the present invention co ⁇ espond to the structures set out in Structure 118.
- n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9.
- the compounds herein co ⁇ espond to Structure 118, as further set out in Table 118.
- R' co ⁇ esponds to a Fragment as previously defined in Figure 6
- B co ⁇ esponds to a Fragment as previously defined in Figure 8
- n indicates the number of linker groups separating Groups R' and B in the respective compounds.
- Groups I, II each have a methyl group
- Groups I*, IE* each have a hydrogen, respectively, in the position designated R in Fragment B of Figure 8.
- the compounds of the present invention co ⁇ espond to the structures set out in Structure 120.
- n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9.
- the compounds herein co ⁇ espond to Structure 120, as further set out in Table 120.
- R' co ⁇ esponds to a Fragment as previously defined in Figure 6
- C co ⁇ esponds to a Fragment as previously defined in Figure 8
- n indicates the number of linker groups separating Groups R' and C in the respective compounds.
- Groups I, II each have a methyl group and Groups I*, II* each have a hydrogen, respectively, in the position designated R in Fragment C of Figure 8.
- the compounds of the present invention co ⁇ espond to the structures set out in Structure 122.
- n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9.
- the compounds herein co ⁇ espond to Structure 122, as further set out in Table 122.
- R' co ⁇ esponds to a Fragment as previously defined in Figure 6
- D co ⁇ esponds to a Fragment as previously defined in Figure 8
- n indicates the number of linker groups separating Groups R' and D in the respective compounds.
- Groups I, II each have a methyl group and Groups I, El each have a hydrogen, respectively, in the position designated R in Fragment D of Figure 8.
- the compounds of the present invention co ⁇ espond to the structures set out in Structure 124.
- n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9.
- the compounds herein co ⁇ espond to Structure 124, as further set out in Table 124.
- R' co ⁇ esponds to a Fragment as previously defined in Figure 6
- E co ⁇ esponds to a Fragment as previously defined in Figure 8
- n indicates the number of linker groups separating Groups R' and E in the respective compounds.
- Groups I, II each have a methyl group and Groups I*, IE* each have a hydrogen, respectively, in the position designated R in Fragment E of Figure 8.
- the compounds of the present invention co ⁇ espond to the structures set out in Structure 126.
- n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9.
- the compounds herein co ⁇ espond to Structure 126, as further set out in Table 126.
- R' co ⁇ esponds to a Fragment as previously defined in Figure 6
- F co ⁇ esponds to a Fragment as previously defined in Figure 8
- n indicates the number of linker groups separating Groups R' and F in the respective compounds.
- Groups I, II each have a methyl group
- Groups I*, IE* each have a hydrogen, respectively, in the position designated R in Fragment F of Figure 8.
- the compounds of the present invention co ⁇ espond to the structures set out in Structure 128.
- n is an integer of from 1 to 12, from 3 to 10, more preferably from 5 to 9, and still more preferably from 6 to 9.
- the compounds herein co ⁇ espond to Structure 128, as further set out in Table 128.
- R' co ⁇ esponds to a Fragment as previously defined in Figure 6
- G co ⁇ esponds to a Fragment as previously defined in Figure 6
- n indicates the number of linker groups separating Groups R' and G in the respective compounds.
- Groups I, II each have a methyl group and Groups I*, El* each have a hydrogen, respectively, in the position designated R in Fragment G of Figure 8.
- Ph phenyl
- OPh O-Phenyl
- diNO 2 dinitric.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 130 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 130 are set out in Table 130.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 132 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein and R is 5-H, 6-CF 3, 5-CH 3 , 5,7-diF, 5,7-diNO 2 , 5-Butyl, 5-iPropyl, 5- Phenyl, 5-NO 2 , 5-Trityl, 5-F, 5-OPh, 5-COPh, 5-CF 3 , 5-COCH 3 , 5-OCH 3 , 5-COOCH 3 or 5-COOH.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 134 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 5-H, 6-CF 3 , 5-CH 3 , 5,7-diF, 5,7-diNO 2 , 5-Butyl, 5-iPropyl, 5- Phenyl, 5-NO 2 , 5-Trityl, 5-F, 5-OPh, 5-COPh, 5-CF 3 , 5-COCH 3 , 5-OCH 3 , 5-COOCH 3 , or 5- COOH.
- Table 134 Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 134 are set out in Table 134.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 136 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 5-H, 6-CF 3 , 5-CH 3 , 5,7-diF, 5,7-diNO 2 , 5-Butyl, 5-iPropyl, 5- Phenyl, 5-NO 2 , 5-Trityl, 5-F, 5-OPh, 5-COPh, 5-CF 3 , 5-COCH 3 , 5-OCH 3 , 5-COOCH 3 , or 5- COOH.
- Table 136 STRUCTURE 136:
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 138 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 5-CF 3 , 5-OPh, 5-iPropyl, 5-COCH 3 , or 5-COPh and Y is 3-N,N- dimethylaminophenyl (3-N,N-diCH 3 ), 4-N,N-dimethylaminophenyl (4-N,N-diCH 3 ), or 2- Ph.
- Table 138 Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 138 are set out in Table 138.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 140 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 5-CF 3 , 5-OPh, 5-iPropyl, 5-COCH 3 or 5-COPh, and Z is CH(Ph) 2 or 3-Pyridyl. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 140 are set out in Table 140.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 142 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 6-CF 3 , 5-OPh, 5-iPropyl, 5-COCH 3 , or 5-COPh. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 142 are set out in Table 142.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 144 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 6-CF 3 , 5-OPh, 5-iPro ⁇ yl, 5-COCH 3 , or 5-COPh. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 144 are set out in Table 144.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 146 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 146 are set out in Table 146.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 148, as further defined in Table 148.
- STRUCTURE 148 :
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 150 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably -from 6 to 9.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 152 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 154 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein Z is CH(DiPh), 4-(N,N-dimethylamino)phenyl, CH 2 CH 2 -(3-pyridy ⁇ ), or (2-phenyl)-phenyl.
- STRUCTURE 154 is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein Z is CH(DiPh), 4-(N,N-dimethylamino)phenyl, CH 2 CH 2 -(3-pyridy ⁇ ), or (2-phenyl)-phenyl.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 156 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is -OCH 3 or -OCH 2 Ph. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 156 are set out in Table 156.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 158 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is -OCH 3 or -OCH 2 Ph. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 158 are set out in Table 158.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 160 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is -OCH 3 or -OCH 2 Ph. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 160 are set out in Table 160.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 162 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is -OCH 3 or -OCH 2 Ph. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 162 are set out in Table 162.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 164 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is -OCH 3 or -OCH 2 Ph. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 164 are set out in Table 164.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 166 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is -OCH 3 or -OCH 2 Ph. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 166 are set out in Table 166.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 168 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is -OCH 3 or -OCH 2 Ph. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 168 are set out in Table 168.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 170 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is -OCH 3 or -OCH 2 Ph. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 170 are set out in Table 170.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 172 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is -OCH 3 and -OCH 2 Ph. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 172 are set out in Table 172.
- STRUCTURE 172 is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is -OCH 3 and -OCH 2 Ph.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 174 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is -OCH 3 and -OCH 2 Ph. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 174 are set out in Table 174.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 176 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein Z is 3-quinoline, 3-(N,N-dimethylamino)phenyl, or 4-(N,N- dimethylamino)phenyl.
- n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein Z is 3-quinoline, 3-(N,N-dimethylamino)phenyl, or 4-(N,N- dimethylamino)phenyl.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 178 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 180 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 182 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 184 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein and R is 6-CF 3 , 5-OPh, 5-CH(CH 3 ) 2 , 5-COCH 3 or 5-COPh.
- STRUCTURE 184 is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein and R is 6-CF 3 , 5-OPh, 5-CH(CH 3 ) 2 , 5-COCH 3 or 5-COPh.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 186 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 6-CF 3 , 5-OPh, 5-CH(CH 3 ) 2 , 5-COCH 3 or 5-COPh. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 186 are set out in Table 186.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 188 wherem n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein and R is 6-CF 3 , 5-OPh, 5-CH(CH 3 ) 2 , 5-COCH 3 or 5-COPh. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 188 are set out in Table 188.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 190 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R is 6-CF 3 , 5-OPh, 5-CH(CH 3 ) 2 , 5-COCH 3 or 5-COPh. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 190 are set out in Table 190.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 192 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein and R is 6-CF 3 , 5-OPh, 5-CH(CH 3 ) 2 , 5-COCH 3 or 5-COPh. Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 192 are set out in Table 192.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 194 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and R 1 is an H or -OCH 2 Ph and R 2 is H or COOCH 3 .
- n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and R 1 is an H or -OCH 2 Ph and R 2 is H or COOCH 3 .
- Table 194 Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 194 are set out in Table 194.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 196 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R 1 is an H or a -OCH 2 Ph and R 2 is H or COOCH 3 . Further prefe ⁇ ed embodiments of the compounds co ⁇ esponding to Structure 196 are set out in Table 196.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 198 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R 1 is an H or a -OCH 2 Ph and R 2 is H, or COOCH 3 .
- n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R 1 is an H or a -OCH 2 Ph and R 2 is H, or COOCH 3 .
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 200 wherein n is an integer of from 1 to 12, more preferably, from 3 to 10, more preferably from 5 to 9 and, still more preferably from 6 to 9 and wherein R 1 is H or a -OCH 2 Ph and R 2 is H or COOCH 3 .
- STRUCTURE 200 is set out in Table 200.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 202.
- R is H or COOCH 3 .
- R j is H
- the compound of Structure 202 is compound 991.
- R, is COOCH 3
- the compound of Structure 202 is compound 992.
- the compounds of the present invention preferably co ⁇ espond to compounds of the Structure 204.
- STRUCTURE 204 :
- R ! is H or COOCH 3 .
- Rj is H the compound of Structure 204 is compound 993.
- R, is COOCH 3 the compound of Structure 206 is 994.
- the present invention comprises compounds of the structures in Table 201 below.
- the compounds of the invention may be readily synthesized using techniques generally known to synthetic organic chemists. Suitable experimental methods for making and derivatizing aromatic compounds are described, for example, methods for making specific and prefe ⁇ ed compounds of the present invention are described in detail in Examples 1 to 4 below.
- This invention preferably further provides a method of generating a library comprising at least one bacterial NAD synthetase enzyme inhibitor compound comprising the steps of: a. obtaining the crystal structure of a bacterial NAD synthetase enzyme; b. identifying one or more sites of catalytic activity on the NAD synthetase enzyme; c. identifying the chemical structure of the catalytic sites on the NAD synthetase enzyme; d. selecting one or more active molecule compounds that will demonstrate affinity for at least one of the catalytic sites on the NAD synthetase enzyme; e.
- the library further comprises one or more compounds set forth in Table 201 above.
- a library of compounds according to the invention herein preferably includes to compounds of the structures set out in structures 1 to 994 above.
- the library comprises a compound of Structure 2, still preferably, Structure 4, further preferably, Structure 6.
- the library comprises at least one compound of Structure 8, Structure 10, Structure 12, Structure 16 or Structure 18.
- the one or more dimeric compounds comprise at least two active molecules. Still preferably, the active molecules are the same. Alternatively, it is preferable that the active molecules are different.
- the invention further provides a software program that predicts the binding affinities of molecules to proteins utilized in the active molecule selection step. Further preferably, a software program that evaluates the chemical and geometric complementarity between a small molecule and macromolecular binding site is utilized in the active molecule selection step.
- the compounds are synthesized utilizing a rapid, solution phase parallel synthesis and wherein the compounds are generated in a combinatorial fashion.
- the invention provides a method of treating or preventing a microbial infection in a mammal comprising administering to the mammal a treatment effective or treatment preventive amount of a bacterial NAD synthetase enzyme inhibitor compound.
- the compound administered in the method is a compound as set out previously in Table 201.
- invention herein preferably includes to compounds 1 to 994 above.
- the compound administered comprises at least one compound of Structure 2, still preferably, Structure 4, further preferably, Structure 6.
- the compounds administered in the method comprise compounds of Structure 8, Structure 10, Structure 12, Structure 16 or Structure 18.
- the invention provides administering a broad spectrum antibiotic to a mammal in need of such treatment or prevention.
- the microbial infection is a bacterial infection.
- the bacterial infection is caused by a bacterium that is a gram negative or gram positive bacteria.
- the bacterial infection may preferably be caused by an antibiotic resistant strain of bacteria.
- Further provided by the invention herein is preferably a method of killing a prokaryote with an amount of prokaryotic NAD synthetase enzyme inhibitor compound to reduce or eliminate the production of NAD whereby the prokaryote is killed.
- a method of decreasing prokaryotic growth comprising contacting the prokaryote with an amount of a prokaryotic NAD synthetase enzyme inhibitor effective to reduce or eliminate the production of NAD whereby prokaryotic growth is decreased is also provided.
- the compound comprises one or more compounds of Table 201.
- the invention comprises one or more of compounds 1 to 994 above.
- the compound administered is a compound of Structure 2, still preferably, a compound of Structure 4, further preferably, Structure 6.
- the compounds administered in the methods compounds of Structure 8, Structure 10, Structure 12, Structure 16 or Structure 18.
- the prokaryote is a bacterium. Further preferably, the bacterium is a gram negative or a gram positive bacteria. Still preferably, the prokaryote is an antibiotic resistant strain of bacteria.
- the NAD synthetase enzyme inhibitor is a compound that selectively binds with catalytic sites or subsites on a bacterial NAD synthetase enzyme to reduce or eliminate the production of NAD by the bacteria.
- the compound is preferably administered by oral, rectal, intramuscularly, intravenous, intravesicular or topical means of administration.
- the compounds of this invention can be administered to a cell of a subject either in vivo or ex vivo.
- the compounds of this invention can be administered orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, subcutaneous injection, transdermally, extracorporeally, topically, mucosally or the like.
- the compounds of the present invention can be in pharmaceutical compositions in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, lotions, creams, gels, or the like, preferably in unit dosage form suitable for single administration of a precise dosage.
- the compositions will include, as noted above, an effective amount of the selected composition, possibly in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc.
- Parenteral administration of the compounds of the present invention is generally characterized by injection.
- Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution of suspension in liquid prior to injection, or as emulsions.
- parenteral administration includes intradermal, subcutaneous, intramuscular, intraperitoneal, intravenous and intratracheal routes.
- One approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained. See e.g., U.S. Patent No. 3,610,795, which is incorporated by reference herein.
- These compounds can be present in a pharmaceutically acceptable carrier, which can also include a suitable adjuvant.
- pharmaceutically acceptable it is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with the selected compound without causing substantial deleterious biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained.
- Routes of administration for the compounds herein are preferably in a suitable and pharmacologically acceptable formulation.
- the bacterial NAD synthetase enzyme inhibitor compounds of the libraries herein are preferably presented to animals or humans orally, rectally, intramuscularly, intravenously, intravesicularly or topically (including inhalation).
- the dosage preferably comprises between about 0.1 to about 15g per day and wherein the dosage is administered from about 1 to about 4 times per day.
- the prefe ⁇ ed dosage may also comprise between 0.001 and 1 g per day, still preferably about 0.01, 0.05, 0.1, and 0.25, 0.5, 0.75 and 1.0 g per day.
- the dosage may be administered in an amount of about 1, 2.5, 5.0, 7.5,10.0, 12.5 and 15.0 g per day.
- the dosage may be administered at a still preferable rate of about 1, 2, 3, 4 or more times per day.
- it may be preferable to administer the compound of the invention continuously, as with, for example, intravenous administration.
- the exact amount of the compound required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the particular compound used, its mode of administration and the like. Thus, it is not possible to specify an exact amount for every compound. However, an appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein.
- cells or tissues can be removed and maintained outside the subject's body according to standard protocols well known in the art.
- the compounds of this invention can be introduced into the cells via known mechanisms for uptake of small molecules into cells (e.g., phagocytosis, pulsing onto class I MHC- expressing cells, liposomes, etc.).
- the cells can then be infused (e.g., in a pharmaceutically acceptable carrier) or transplanted back into the subject per standard methods for the cell or tissue type. Standard methods are known for transplantation or infusion of various cells into a subject.
- the compound utilized for contacting comprises one or more compounds of Table 201.
- the compounds utilized for contacting may also comprise one or more of compounds 1 to 994.
- the compound utilized for contacting is a compound of Structure 2, still preferably, a compound of Structure 4, further preferably, Structure 6.
- the compounds utilized for contacting in the method comprise compounds of Structure 8, Structure 10, Structure 12, Structure 16 or Structure 18.
- the compounds of the present invention are effective as disinfectant materials for, for example, hard or soft surfaces, fabrics, and other contaminated materials such as those in hospitals, households, schools, nurseries, and any other location.
- the invention provides a method for disinfecting comprising contacting a bacterial contaminated material with a bacterial NAD synthetase enzyme inhibitor compound.
- an in vitro "one-at-a-time" method of screening compounds for bacterial NAD synthetase enzyme inhibitory activity comprises the steps of preparing a solution comprising pure bacterial NAD synthetase enzyme, contacting the solution with the compounds set out herein, and determining the rate of the enzyme-catalyzed reaction.
- measurement of the rate of enzyme- catalyzed reaction comprises a measure of NAD synthetase inhibitory activity.
- the rate of enzyme-catalyzed reaction comprises a measure of antibacterial activity.
- the rate of enzyme-catalyzed reaction co ⁇ esponds to a measure of antimicrobial activity.
- the method of preparing the bacterial enzyme solution for use in the in vitro screening method comprises utilizing molecular biological methods to over-express bacterial NAD synthetase enzyme, for example from B. subtilis, in E. coli.
- molecular biological methods to over-express bacterial NAD synthetase enzyme, for example from B. subtilis, in E. coli.
- a particularly preferable method comprises: a) cloning the Out B gene encoding NAD synthetase enzyme and over- expressing the gene in E.
- bacterial NAD synthetase enzyme is essentially pure
- essentially pure means greater than about 90% purity, more preferably, greater than about 95% purity and, still more preferably, greater than about 99% purity.
- the following procedure is utilized to measure the rate of enzyme catalyzed reaction.
- a solution of HEPPS, pH 8.5, with KCl is prepared containing the following species: ATP, NaAD, MgCl 2 , NH 4 C1, ADH, and ETOH.
- a stock solution of test inhibitors is then prepared by dissolving solid samples into 100% DMSO.
- the test compound stock solution is then added to the mixture to give the final test compound concentrations.
- NAD synthetase enzyme solution is added, the mixture is mixed three times, and the absorbance at 340 nm is then monitored kinetically using an UV-Vis spectrophotometer.
- IC 50 (concentration needed to inhibit 50% of the test bacteria) values were obtained for select compounds by assaying six different concentrations of test compound, in triplicate, at concentrations between 0.0 and 2.0 mM, and plotting the resulting % inhibition values against the -LOG of the test compound dose to reveal the concentration at which 50% inhibition is observed.
- the in vitro method can also be adapted to allow screening for compounds with bacterial NAD synthetase enzyme inhibitory activity in other forms of bacteria, as well as other types of microbes.
- the above-described procedure can be adapted to screen for inhibitory activity in at least the following bacteria types: BACTERIUM STRAIN
- the method can be used to screen existing compounds e.g., commercially available compounds, such as 5- nitroindole and N-methyl nicotinic acid.
- commercially available compounds such as 5- nitroindole and N-methyl nicotinic acid.
- One of skill in the art will recognize the manner in which the designing and screening methods herein can be utilized to identify commercially available compounds, such as the previous non-exhaustive list, that will exhibit NAD synthetase enzyme inhibitory activity, both in bacteria and other microbes.
- the potential inhibitory activity of the library of synthetic compounds in one embodiment is assessed via a coupled enzymatic assay.
- the coupled assay involves two steps as summarized below.
- the invention provides a high through-put screening system (HTS system).
- the HTS system preferably utilizes an integrated robotic system that coordinates the functions of a liquid handler and a spectrophotometer.
- the robotic station is preferably responsible for the movement of all hardware and the integration of multiple stations on the worksurface.
- the liquid handler is preferably programmed to perform all phases of liquid dispensing and mixing.
- the spectrophotometer is preferably equipped to monitor absorbance in a 96-well plate format.
- the assay is designed for a 96-well plate format reaction buffer containing HEPPS buffer, pH 8.5, MgCl 2 , NH 4 CL 2 , KCL, NaAD, n-Octyl-D- Glucopyranoside, ethanol, NAD synthetase, and yeast alcohol dehydrogenase.
- the liquid handler dispenses DMSO (with or without inhibitor) into the reaction well.
- the liquid handler mixes these components utilizing a predefined mixing program.
- the reaction is initiated by the addition of a solution of ATP dissolved in buffer.
- the reaction is monitored by measuring the increase in absorbance at 340nm.
- the linear portion of the reaction is monitored for a period of time. The initial velocity is determined using the software supplied with the spectrophotometer.
- the compounds of the library herein are supplied as a stock with a concentration dissolved in 100% DMSO.
- An initial screen is conducted on all compounds using a 2 or 3 concentration screen.
- the 2 panel screen used concentrations of 0.2mM and O.lmM for the compounds.
- the 3 panel screen used concentrations of 0.2mM, O.lmM, and 0.05mM.
- "lead compounds” e.g., those compounds which demonstrated the greatest inhibitory capacity, are then preferably subjected to a wider screen of concentrations (O.lmM to 0.00 ImM) to determine the apparent IC-50 values for each compound.
- the high throughput method is utilized to screen commercially available compounds for bacterial NAD synthetase enzyme inhibitory activity.
- the NAD synthetase enzyme inhibitor compounds are tested as inhibitors of bacterial growth against a variety of bacteria types.
- compounds within the libraries of NAD synthetase inhibitor compounds are evaluated for antibacterial and antimicrobial activity.
- compounds are preferably evaluated for their potential to inhibit the growth of Bacillus subtilis, Pseudomonas aeruginosa, and Staphoyloccus epidermitis.
- the inhibitors are preferably initially screened in duplicate at one concentration.
- the test inhibitor compounds are prepared by dissolving the solid samples in DMSO. Aliquots from the inhibitor stocks are placed in sterile 96-well plates by the liquid handler discussed previously. Cultures of B. subtilis, P. aeruginosa and S. epidermitis are prepared in liquid broth (LB) media and incubated in an orbital shaker overnight. Dilutions (with LB media) of the overnight cultures are added to the 96-well plates containing the inhibitors. The plates are incubated and the absorbance measured at 595nm in a plate reader.
- a diluted overnight culture without inhibitors serves as one of three controls in the experiments.
- a positive control which includes an identical concentration of the drug Tobramycin as the inhibitors being tested, and a DMSO control are also performed during each inhibitor screen.
- dose responses are performed on the compounds that inhibited greater than 85% in the initial screen.
- the dose responses consisted of 5 different concentrations (from 100 mM - 0.1 mM) of each inhibitor and the positive control Tobramycin.
- the cultures are prepared and grown in the same manner as the inhibitor screens and the same controls were included.
- the absorbance is measured every hour and a half during the six hours of growth. Percent inhibitions are calculated again for each concentration tested. The lowest concentration that resulted in an 85% inhibition or higher is termed the Minimum Inhibitory Concentration that inhibited bacterial growth 85% (MIC 85 ).
- NAD synthetase enzyme inhibitor compound of a library herein When a NAD synthetase enzyme inhibitor compound of a library herein are to be administered to a humans or an animal e.g. a mammal, it is preferable that the compounds show little or no toxicity to the patient. Therefore, in one embodiment of the invention herein, the toxicities of the NAD-synthetase enzyme inhibitors are evaluated using human epithelial cells as set out in Example 10 below.
- Example 1 describes one embodiment of the invention herein for compounds prepared according to the synthetic pathway set out in Scheme 3, described previously.
- the linker length e.g., n is equal to 6.
- Compounds prepared according this embodiment were prepared, individually, i.e., not using parallel solution phase synthesis methods.
- One of skill in the art will readily recognize the manner in which the following Example may be varied to obtain the linker lengths within the scope of the present invention.
- the product was then purified by flash chromatography on silica gel using hexane-acetone (9:3) to afford the product (0.39 g) and deacetylated product (1.11 g, for a combined yield 91.2%).
- the acetylated product was isolated as a yellow colored viscous oil.
- EXAMPLE 2 GENERAL EXPERIMENTAL PROCEDURES USED FOR PREPARING SOLUTION PHASE COMBINATORIAL LIBRARIES DESCRIBED IN SCHEME 4.
- Example 2 describes a prefe ⁇ ed embodiment of the invention herein for compounds prepared according to the synthetic pathway set out in Scheme 4, described previously.
- One of skill in the art will recognize that many possible variations on this embodiment exist that will not result in deviation from the novel and unobvious aspects of the invention.
- A. Alkylation of 5-nitroindole with the bromoalkyl acetate and conversion of the indole alkyl acetate to the alcohol.
- a solution of 5-nitroindole (lg, 6.17mmol) in DMF (lO.OmL) was prepared in 4 dram vials (size 28 X 57mm) This solution was then transfe ⁇ ed to a second 4 dram vial containing a suspension of NaH (0.22g, 9.25mmol) in DMF (8.0mL).
- a nitrogen inlet was used to prevent gas pressure build up.
- the robotic synthesizer was then used to dispense 3.0mL of the indole sodium salt solution into 5 culture tubes (16 X 125mm) in a synthesizer block.
- the bromoalkyl acetate (1.36mmol) was dissolved in DMF (8mL total volume, 1.36M solution) in a 4 dram vial, lmL of this solution was transfe ⁇ ed into designated test tubes using the robotic synthesizer. After allowing the reaction to block shake for 15 hours at ambient temperature, tris(2-aminoethyl)amine resin (0.15g, 0.329mmol) was added and the reaction was shaken for 12 hours with heating at 55 °C. The resin was filtered using 3cc syringes each with a cotton plug and connected to a 24-port manifold and a water aspirator provided vacuum suction.
- the filtrate was collected in culture tubes (16 X 125mm) and the resin was washed using MeOH (3.0mL). Prior to placing the tubes in the reaction block a catalytic amount of NaH (10-12mg) was added to each tube and allowed to shake at ambient temperature for 12 hours. Work-up consisted of adding ethyl acetate (4.0mL) and water (3.0mL) to each sample, shaking and removing the organic layer then subsequently washing the organic layer using brine (2 X 3.0mL).
- the organic layer was dried over anhydrous NajSO,,, filtered vide supra, and the solvent was transfe ⁇ ed to 4 dram vials evaporated using a speed vac to give the alcohol as a solid residue whose weight range was from lOOmg to 226mg.
- EXAMPLE 3 GENERAL EXPERIMENTAL PROCEDURES USED FOR PREPARING SOLUTION PHASE COMBINATORIAL LIBRARIES DESCRIBED IN SCHEME 5
- Example 3 describes a prefe ⁇ ed embodiment of the invention herein for compounds prepared according to the synthetic pathway set out in Scheme 5, described previously.
- One of skill in the art will recognize that many possible variations on this embodiment exist that will not result in deviation from the novel and unobvious aspects of the invention A.
- Methyl and benzyl esters of indole carboxylates Potassium carbonate (0.55 eq) was added to indole carboxylic acid (6.1 mmol) sti ⁇ ed in dry DMF (10 mL) at r.t. After 10 min., the alkyl iodide (benzyl or methyl) (1.1 eq) was added.
- Each culture tube was treated with a polymer supported trapping resin, tris(2- aminoethyl)amine (0.16 eq, 0.046 mmol), and the tubes were shaken at 50°C for 6.5 hours.
- the mixture was filtered through cotton in 1 mL syringes using a 24 port manifold, the filter was washed with dry MeOH (2 mL), and the filtrate was collected and concentrated in 100x13 mm culture tubes to provide the product.
- reaction mixture was diluted with EtOAc (3mL) and washed with 1 N HCl (3x1 mL), water (2x1 mL) and brine (1 mL). The solution was dried (Na ⁇ O and concentrated on the speed- vac under reduced pressure to provide the product.
- EXAMPLE 4 GENERAL EXPERIMENTAL PROCEDURES USED FOR PREPARING SOLUTION PHASE COMBINATORIAL LIBRARIES DESCRIBED IN SCHEME 6
- Example 4 describes a prefe ⁇ ed embodiment of the invention herein for compounds prepared according to the synthetic pathway set out in Scheme 6, described previously.
- One of skill in the art will recognize that many possible variations on this embodiment exist that will not result in deviation from the novel and unobvious aspects of the invention.
- ester To an anhydrous DMF solution (2 mL) of the indole mesylate (1 eq.) in 10 x 1.3 cm test tubes was added the co ⁇ esponding carboxylic acid (R 3 -COOH, 2 eq.) followed by K 2 CO 3 (2 eq.) and glass beads at room temperature. The resulting suspension was heated to 55 °C for 16 h under vigorous vortex shaking. Upon cooling the reaction mixture was quenched by adding water (3 mL) followed by ethyl acetate (3 mL). The organic layer was washed with brine (4 mL), dried under MgSO 4 , filtered through a cotton bed (in 5 mL disposable syringes) and concentrated under high vacuum (speed-vac) to give the final ester.
- R 3 -COOH co ⁇ esponding carboxylic acid
- K 2 CO 3 2 eq.
- EXAMPLE 5 GENERAL PROCEDURE FORCRYSTALLIZATION, DATA COLLECTION AND DETERMINAITON OF STRUCTURAL RELATIONSHIP BETWEEN NAD SYNTHETASE INHIBITOR COMPOUNDS AND THE NAD SYNTHETASE ENZYME.
- Inhibitors were dissolved in minimal volume of PEG 400 and then mixed with crystallization medium to final concentration of 5 - 10 mM in 23% v/v PEG 400.
- 10 ⁇ l of protein solution (16 mg/ml in crystallization buffer) were mixed with 10 ⁇ L of inhibitor in crystallization medium incubated at 28 ° C.
- the crystals of NAD synthetase complexed with inhibitors obtained belonged to space group P21 as described previously in the literature. (Rizzi, M., Nessi, C, Matteve, A., Coda, A. & Galizzi, A. Crystal structure of NH 3 -dependent NAD + synthetase from Bacillus subtilis. EMBO Journal 15, 5125-5134 (1996)).
- Inhibitors were manually built into (F 0 -F c ) ⁇ c difference Fourier maps using QUANTA ( Molecular Simulations ) (Jones, T., Zou, J., Cowan, S. & Kjeldgaard, M. Improved method for building protein models in electron density maps and the location of the errors in these models. Acta Crystallogr. A 47, 110-119 (1991)) and O and refinement continued. A bulk solvent co ⁇ ection were then applied and ordered water molecules added following standard criteria.
- the "one-at-a-time" in vitro bacterial NAD synthetase enzyme activity assay described below was used to test for relative activities of selected active molecules and synthetic dimers.
- the method was used to test selected NAD synthetase inhibitor compounds of the library herein, as well as commercially available compounds predicted to have bacterial NAD synthetase enzyme activity inhibitor capabilities.
- a solution (1014 L) of 60 mM HEPPS pH 8.5 with 20 mM KCl was prepared containing the following species: 0.210 mM ATP, 0.152 mM NaAD, 4 mM MgCl 2 , 10 mM NH 4 C1, 0.21 mg/mL ADH, and 1% ETOH.
- a stock solution of test inhibitors was then prepared by dissolving solid samples into 100% DMSO. 20 L of the test compound stock solution was then added to the mixture to give the final test compound concentrations listed.
- IC 50 values were obtained for select compounds by assaying six different concentrations of test compound, in triplicate, at concentrations between 0.0 and 2.0 mM, and plotting the resulting % inhibition values against the -LOG of the test compound dose to reveal the concentration at which 50% inhibition was observed.
- Compound 864 demonstrates inhibitory activity from which bacterial NAD synthetase inhibitory activity in a variety of bacteria may be extrapolated. Further, it is evident from this data that inhibition of bacterial NAD synthetase enzyme co ⁇ esponds to inhibition of both gram positive and gram negative bacteria. Such data also demonstrates the effectiveness of the compounds herein as bacteriacidal agents, antimicrobial agents and disinfectants.
- EXAMPLE 8 ADAPTATION OF ENZYME ASSAY TO HIGH THROUGH-PUT SCREENING OF INHIBITORS
- the final reaction mixture included 0.2ml of 60mM HEPPS buffer, pH 8.5, lOmM MgCl 2 , 19mM NH 4 CL 2 , 20mM KCL, O.lmM NaAD, 0.3% n-Octyl ⁇ D-Glucopyranoside, 1% ethanol, lg/ml NAD synthetase, 62.5g/ml yeast alcohol dehydrogenase, 0.2mM ATP and 2.5% DMSO.
- the measurement of inhibitory activities of the test compounds was conducted using a high through-put screening system (HTS system).
- HTS system utilizes an integrated Sagian 2M ORCA robotic system coordinating the functions of a Beckman Biomek 2000 liquid handler and a Molecular Devices SpectraMax Plus spectrophotometer.
- the 2M ORCA robotic station was responsible for the movement of all hardware and the integration of multiple stations on the worksurface.
- the Biomek 2000 is programmed to perform all phases of liquid dispensing and mixing.
- the SpectraMax Plus spectrophotometer was equipped to monitor absorbance in a 96- well plate format.
- the present assay was designed for a 96-well plate format and begun with the dispensing of 0.170ml of reaction buffer containing 60mM HEPPS buffer, pH 8.5, lOmM MgCl 2 , 19mM NH 4 CL 2 , 20mM KCL, 0.118mM NaAD, 0.3% n-Octyl-D- Glucopyranoside, 1.18% ethanol, 1.18g/ml NAD synthetase, and 73.75g/ml yeast alcohol dehydrogenase.
- a 0.005ml volume of test compound in 100% DMSO or a 0.005ml of DMSO was dispensed in the reaction well.
- the Biomek 2000 mixed these components utilizing a predefined mixing program.
- the reaction was initiated by the addition of 0.025ml of a solution of 1.6mM ATP dissolved in 60mM HEPPS buffer, pH 8.5, lOmM MgCl 2 , 19mM NH 4 CL 2 , 20mM KCL, 2.5% DMSO, and 0.3% n-Octyl-D-Glucopyranoside.
- the reactions were monitored by measuring the increase in absorbance at 304nm.
- the linear portion of the reaction was monitored for 180sec.
- the initial velocity was determined using Softmax Pro, the software supplied with the Molecular Devices SpectraMax Plus spectrophotometer.
- the compounds were supplied as a stock with a concentration of 50mM dissolved in 100% DMSO.
- An initial screen was conducted on all compounds using a 2 or 3 concentration screen.
- the 2 panel screen used concentrations of 0.2mM and O.lmM for the compounds.
- the 3 panel screen used concentrations of 0.2mM, O.lmM, and 0.05mM. From the initial screen, lead compounds which indicated the greatest inhibitory capacity were then subjected to a wider screen of concentrations (O.lmM to 0.005mM) to determine the apparent IC-50 values for each compound.
- Double reciprocal plots of initial velocities have yielded the kinetic parameters given in the following table for the 2 mL cuvette assay. Also included in the table are the Km values obtained in the 0.2 mL microtiter plate assay. In this latter assay, a Beckmann/Sagian automated robotic system was applied in for high through-put screening in one prefe ⁇ ed embodiment of the method.
- Table 218 sets forth the various potent compounds ("lead compounds") of the NAD synthetase enzyme inhibitor compound libraries disclosed herein.
- the potency of the compounds is expressed according to IC 50 values.
- the IC 50 value is that amount of NAD synthetase enzyme inhibitor compound required to inhibit the enzyme by 50%.
- Table 220 sets out screening results for a selection of compounds from the libraries of bacterial NAD synthetase enzyme inhibitor compounds of the invention herein. As apparent from the table, all compounds tested exhibit some inhibitory activity against Staphylococcus epidermitis and, accordingly, the compounds exhibit effectiveness as antimicrobial agents, antibacterial agents and disinfecting agents.
- Table 222 sets out the MIC 85 (minimum inhibitory concentration to achieve 85% inhibition) values against B. subtilis (gram positive bacteria) for a number of lead compounds within a library of bacterial NAD synthetase enzyme inhibitor compounds from Table 201 above and of the invention herein. This table demonstrates that the compounds of the invention herein are useful as antibacterial agents, antimicrobial agents and disinfecting agents.
- Table 224 sets out the MIC 85 (minimum inhibitory concentration to achieve 85% inhibition) against Staphylococcus epidermitis for a number of compounds within a library of bacterial NAD synthetase enzyme inhibitor compounds of the invention herein. This table demonstrates that the compounds of the invention herein are useful as antibacterial agents, antimicrobial agents and disinfecting agents.
- EXAMPLE 10 IN VITRO TOXICITY IN HUMAN CELLS OF SELECTED COMPOUNDS WITHIN THE LIBRARY OF COMPOUNDS
- the cells were washed once with medium, centrifuged, and resuspended in 2% bovine serum albumin/phosphate-buffered saline. The cell suspension was then run through a FACSaliber flow cytometer and approximately 5000 cells were counted. The proportion of dead (stained) cells was determined, and the percent of live cells was expressed as % controls. The minimum toxic concentration was the lowest tested concentration of inhibitor which caused a significantly lower percentage of live cells as compared to controls.
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU20317/99A AU2031799A (en) | 1998-01-14 | 1999-01-14 | Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme |
IL13722999A IL137229A0 (en) | 1998-01-14 | 1999-01-14 | Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme |
DE69918799T DE69918799D1 (de) | 1998-01-14 | 1999-01-14 | Verfahren zur herstellung und screening von inhibitoren des bakteriellen nad synthetase enzyms, verbindungen daraus und methoden zur behandlung bakterieller und mikrobieller infektionen mit diesen inhibitoren |
JP2000540138A JP2002509149A (ja) | 1998-01-14 | 1999-01-14 | 細菌nadシンテターゼ酵素の阻害剤の合成およびスクリーニング方法、その化合物、ならびに細菌nadシンテターゼ酵素の阻害剤を用いる細菌および微生物感染の治療方法 |
CA002317439A CA2317439A1 (en) | 1998-01-14 | 1999-01-14 | Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme |
AT99900821T ATE271555T1 (de) | 1998-01-14 | 1999-01-14 | Verfahren zur herstellung und screening von inhibitoren des bakteriellen nad synthetase enzyms, verbindungen daraus und methoden zur behandlung bakterieller und mikrobieller infektionen mit diesen inhibitoren |
EP99900821A EP1047692B1 (en) | 1998-01-14 | 1999-01-14 | Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof and methods of treating bacterial and microbial infections with these inhibitors |
DE69913712T DE69913712T2 (de) | 1998-08-25 | 1999-06-30 | Inhibitoren der bakteriellen nad synthetase |
AU49639/99A AU4963999A (en) | 1998-08-25 | 1999-06-30 | Inhibitors of bacterial nad synthetase |
EP99933622A EP1109805B1 (en) | 1998-08-25 | 1999-06-30 | Inhibitors of bacterial nad synthetase |
CA002341506A CA2341506A1 (en) | 1998-08-25 | 1999-06-30 | Inhibitors of bacterial nad synthetase |
JP2000566269A JP2002523412A (ja) | 1998-08-25 | 1999-06-30 | 細菌nadシンテターゼ阻害剤 |
AT99933622T ATE256677T1 (de) | 1998-08-25 | 1999-06-30 | Inhibitoren der bakteriellen nad synthetase |
PCT/US1999/014839 WO2000010996A1 (en) | 1998-08-25 | 1999-06-30 | Inhibitors of bacterial nad synthetase |
IL14151399A IL141513A0 (en) | 1998-08-25 | 1999-06-30 | Inhibitors of bacterial nad synthetase |
US09/617,258 US6500852B1 (en) | 1998-01-14 | 2000-07-14 | Inhibitors of bacterial NAD synthetase |
US10/080,279 US6861448B2 (en) | 1998-01-14 | 2002-02-22 | NAD synthetase inhibitors and uses thereof |
US10/281,407 US6727237B2 (en) | 1998-01-14 | 2002-10-25 | Inhibitors of bacterial NAD synthetase |
AU2003261481A AU2003261481A1 (en) | 1998-08-25 | 2003-11-06 | Inhibitors of bacterial NAD synthetase |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7139998P | 1998-01-14 | 1998-01-14 | |
US60/071,399 | 1998-01-14 | ||
US9788098P | 1998-08-25 | 1998-08-25 | |
US60/097,880 | 1998-08-25 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/014839 Continuation-In-Part WO2000010996A1 (en) | 1998-01-14 | 1999-06-30 | Inhibitors of bacterial nad synthetase |
US09/617,258 Continuation US6500852B1 (en) | 1998-01-14 | 2000-07-14 | Inhibitors of bacterial NAD synthetase |
US09/617,258 Continuation-In-Part US6500852B1 (en) | 1998-01-14 | 2000-07-14 | Inhibitors of bacterial NAD synthetase |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999036422A1 true WO1999036422A1 (en) | 1999-07-22 |
Family
ID=26752172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/000810 WO1999036422A1 (en) | 1998-01-14 | 1999-01-14 | Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme |
Country Status (9)
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001000197A2 (en) * | 1999-06-29 | 2001-01-04 | The Uab Research Foundation | Methods of treating fungal infections with inhibitors of nad synthetase enzyme |
WO2001055443A1 (en) * | 2000-01-31 | 2001-08-02 | Pharmacia & Upjohn Company | Crystallization and structure determination of staphylococcus aureus nad synthetase |
WO2002007516A2 (en) * | 2000-07-14 | 2002-01-31 | The Uab Research Foundation | Uses for nad synthetase inhibitors |
WO2001023330A3 (en) * | 1999-09-29 | 2002-05-10 | Upjohn Co | Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules |
US6500852B1 (en) | 1998-01-14 | 2002-12-31 | University Of Alabama Research Foundation | Inhibitors of bacterial NAD synthetase |
US6673827B1 (en) | 1999-06-29 | 2004-01-06 | The Uab Research Foundation | Methods of treating fungal infections with inhibitors of NAD synthetase enzyme |
US6677160B1 (en) | 1999-09-29 | 2004-01-13 | Pharmacia & Upjohn Company | Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules |
US6764858B2 (en) | 1999-09-29 | 2004-07-20 | Pharmacia & Upjohn Company | Methods for creating a compound library |
WO2005002337A1 (en) * | 2003-04-02 | 2005-01-13 | Virtual Drug Development, Inc. | Disinfectant compositions and methods |
US6861448B2 (en) | 1998-01-14 | 2005-03-01 | Virtual Drug Development, Inc. | NAD synthetase inhibitors and uses thereof |
WO2005054198A2 (en) * | 2003-12-05 | 2005-06-16 | University Of Bath | Therapeutics use of pyridinium compounds to modulate naadp activity |
EP1652839A2 (en) * | 1999-10-28 | 2006-05-03 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
US7056917B2 (en) | 2001-04-26 | 2006-06-06 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
WO2007005845A1 (en) * | 2005-07-01 | 2007-01-11 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
US7514457B2 (en) | 2005-05-31 | 2009-04-07 | Pfizer Inc. | Substituted aryloxymethyl bicyclicmethyl acetamide compounds |
US7696240B2 (en) | 2005-12-15 | 2010-04-13 | Hoffmann-La Roche Inc. | Fused pyrrole derivatives |
US8710232B2 (en) | 2004-04-22 | 2014-04-29 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives used as TAFIa inhibitors |
US8940901B2 (en) | 2010-11-11 | 2015-01-27 | Sanofi | Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives |
US8993560B2 (en) | 2011-03-11 | 2015-03-31 | Glaxo Group Limited | Compounds |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003245575A1 (en) * | 2002-06-19 | 2004-01-06 | University Of Rochester | Oligonucleotide directed misfolding of rna |
ES2386721T3 (es) * | 2003-06-27 | 2012-08-28 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Compuestos de piridinio anfifilos , método de fabricación y utilización de los mismos |
JP5629447B2 (ja) * | 2009-10-07 | 2014-11-19 | 株式会社セイシン企業 | 粒子性状の測定方法及び装置並びに測定試料の調製装置 |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
JP6064062B2 (ja) | 2013-03-15 | 2017-01-18 | ファイザー・インク | Ampkを活性化させるインダゾール化合物 |
CN110074138B (zh) * | 2019-06-18 | 2020-05-08 | 江西顺泉生物科技有限公司 | 一种解淀粉芽孢杆菌油悬浮剂 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4289777A (en) * | 1978-12-28 | 1981-09-15 | Schering, Aktiengesellschaft | Quinolonecarboxylic acid derivatives and pharmaceutical preparations thereof for treatment of an allergic disease of the respiratory tract |
EP0585722A1 (en) * | 1992-08-21 | 1994-03-09 | Eisai Co., Ltd. | Benzimidazole derivatives as antimicrobal agent against Campylobacter pylon |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4275068A (en) | 1977-08-29 | 1981-06-23 | Siegfried Ag | Lipid lowering alkylene glycols and ester derivatives thereof |
US4544741A (en) | 1982-03-29 | 1985-10-01 | Robins Roland K | Azole dinucleotide compounds and methods for their production |
US5206146A (en) | 1983-04-25 | 1993-04-27 | Asahi Kasei Kogyo Kabushiki Kaisha | Assay method using NAD synthetase |
JPS59198995A (ja) | 1983-04-25 | 1984-11-10 | Toyo Jozo Co Ltd | Nad合成酵素を用いる測定法 |
JPS60120987A (ja) | 1983-12-05 | 1985-06-28 | Kikkoman Corp | 固定化された微生物菌体もしくは酵素の製法 |
US4616008A (en) * | 1984-05-02 | 1986-10-07 | Takeda Chemical Industries, Ltd. | Antibacterial solid composition for oral administration |
EP0196530A3 (de) | 1985-03-26 | 1989-03-22 | CTA Finanz AG | Mittel und Verfahren zur Beschleunigung des Wachstums, zur Optimierung der Fruchtbarkeit und zur Stimulierung des Immunsystems bei Mensch und Tier |
GB8607294D0 (en) | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
US4921786A (en) | 1986-09-10 | 1990-05-01 | Toyo Jozo Kabushiki Kaisha | Novel NAD synthetase, assay method using said novel NAD synthetase and a process for production thereof |
FI90544C (fi) | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
JP2694361B2 (ja) | 1989-02-09 | 1997-12-24 | アストラ アクチエボラグ | 抗菌剤 |
DE69014141T2 (de) | 1989-02-10 | 1995-05-24 | Takeda Chemical Industries Ltd | Verwendung von Benzimidazol-Derivaten als antibakterielle Mittel. |
CZ284437B6 (cs) | 1991-04-17 | 1998-11-11 | Hoechst Marion Roussel, Inc. | Substituované (pyridinylamino)-benzisoxazoly a -benzo[b]thiofeny, způsob jejich přípravy farmaceutický prostředek obsahující tyto sloučeniny a použití těchto sloučenin |
HUT69705A (en) | 1991-11-25 | 1995-09-28 | Pfizer | Indole derivatives |
EP0561626B1 (en) | 1992-03-17 | 1998-08-12 | Unitika Ltd. | A method for enzymatic analysis and reagent therefor |
CA2155759A1 (en) | 1993-03-29 | 1994-10-13 | Bernd Janssen | 1-amino-3-phenoxy propane derivatives as modulators of multi-drug resistance |
IT1271352B (it) | 1993-04-08 | 1997-05-27 | Boehringer Ingelheim Italia | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale |
GB9317764D0 (en) | 1993-08-26 | 1993-10-13 | Pfizer Ltd | Therapeutic compound |
GB9320115D0 (en) | 1993-09-29 | 1993-11-17 | Glaxo Group Ltd | Process |
US5468768A (en) | 1994-01-06 | 1995-11-21 | Bristol-Myers Squibb Company | Antimigraine derivatives of indolylcycloalkanylamines |
AU3162695A (en) | 1994-08-03 | 1996-03-04 | Asta Medica Aktiengesellschaft | Indol, indazol, pyridopyrrol and pyridopyrazol derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immunomodulating effects |
JP3720395B2 (ja) | 1994-09-20 | 2005-11-24 | 京都薬品工業株式会社 | 新規ヘテロ環誘導体、その製造方法およびその医薬用途 |
US5521197A (en) | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
AU4536096A (en) | 1995-01-10 | 1996-07-31 | Smithkline Beecham Spa | Indole derivatives useful in the treatment of osteoporosis |
AU718434B2 (en) | 1995-02-17 | 2000-04-13 | Mitsubishi-Tokyo Pharmaceuticals, Inc. | Process for producing indoline compounds and intermediates for the production of the same |
CA2215322A1 (en) | 1995-03-20 | 1996-09-26 | Stephen Warren Kaldor | 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)-and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists |
US6037123A (en) | 1995-09-15 | 2000-03-14 | Microcide Pharmaceuticals, Inc. | Methods of screening for compounds active on Staphylococcus aureus target genes |
ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
US5849764A (en) | 1995-12-14 | 1998-12-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
FR2744452B1 (fr) | 1996-02-06 | 1998-03-06 | Cird Galderma | Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations |
US5998438A (en) | 1996-11-26 | 1999-12-07 | Allelix Biopharmaceuticals, Inc. | 5-cyclo indole compounds |
US5981550A (en) | 1997-06-05 | 1999-11-09 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
US6046136A (en) | 1997-06-24 | 2000-04-04 | Zeneca Limited | Herbicidal heterocyclic N-oxides compounds |
US5932743A (en) | 1997-08-21 | 1999-08-03 | American Home Products Corporation | Methods for the solid phase synthesis of substituted indole compounds |
WO1999012951A1 (en) | 1997-09-11 | 1999-03-18 | Oxigene, Inc. | Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases |
IL137229A0 (en) | 1998-01-14 | 2001-07-24 | Uab Research Foundation | Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme |
EP1109805B1 (en) | 1998-08-25 | 2003-12-17 | The Uab Research Foundation | Inhibitors of bacterial nad synthetase |
US6174873B1 (en) | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
-
1999
- 1999-01-14 IL IL13722999A patent/IL137229A0/xx unknown
- 1999-01-14 AT AT99900821T patent/ATE271555T1/de not_active IP Right Cessation
- 1999-01-14 AU AU20317/99A patent/AU2031799A/en not_active Abandoned
- 1999-01-14 DE DE69918799T patent/DE69918799D1/de not_active Expired - Lifetime
- 1999-01-14 CA CA002317439A patent/CA2317439A1/en not_active Abandoned
- 1999-01-14 JP JP2000540138A patent/JP2002509149A/ja active Pending
- 1999-01-14 WO PCT/US1999/000810 patent/WO1999036422A1/en active IP Right Grant
- 1999-01-14 EP EP99900821A patent/EP1047692B1/en not_active Expired - Lifetime
-
2000
- 2000-07-14 US US09/617,258 patent/US6500852B1/en not_active Expired - Fee Related
-
2002
- 2002-10-25 US US10/281,407 patent/US6727237B2/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4289777A (en) * | 1978-12-28 | 1981-09-15 | Schering, Aktiengesellschaft | Quinolonecarboxylic acid derivatives and pharmaceutical preparations thereof for treatment of an allergic disease of the respiratory tract |
EP0585722A1 (en) * | 1992-08-21 | 1994-03-09 | Eisai Co., Ltd. | Benzimidazole derivatives as antimicrobal agent against Campylobacter pylon |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6500852B1 (en) | 1998-01-14 | 2002-12-31 | University Of Alabama Research Foundation | Inhibitors of bacterial NAD synthetase |
US6861448B2 (en) | 1998-01-14 | 2005-03-01 | Virtual Drug Development, Inc. | NAD synthetase inhibitors and uses thereof |
US6727237B2 (en) | 1998-01-14 | 2004-04-27 | Wayne J. Brouillette | Inhibitors of bacterial NAD synthetase |
WO2001000197A2 (en) * | 1999-06-29 | 2001-01-04 | The Uab Research Foundation | Methods of treating fungal infections with inhibitors of nad synthetase enzyme |
WO2001000197A3 (en) * | 1999-06-29 | 2001-09-07 | Uab Research Foundation | Methods of treating fungal infections with inhibitors of nad synthetase enzyme |
US6673827B1 (en) | 1999-06-29 | 2004-01-06 | The Uab Research Foundation | Methods of treating fungal infections with inhibitors of NAD synthetase enzyme |
WO2001023330A3 (en) * | 1999-09-29 | 2002-05-10 | Upjohn Co | Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules |
US6677160B1 (en) | 1999-09-29 | 2004-01-13 | Pharmacia & Upjohn Company | Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules |
US6764858B2 (en) | 1999-09-29 | 2004-07-20 | Pharmacia & Upjohn Company | Methods for creating a compound library |
US7377894B2 (en) | 1999-09-29 | 2008-05-27 | Pharmacia & Upjohn Company | Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules |
EP1652839A3 (en) * | 1999-10-28 | 2006-07-05 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
EP1652839A2 (en) * | 1999-10-28 | 2006-05-03 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
WO2001055443A1 (en) * | 2000-01-31 | 2001-08-02 | Pharmacia & Upjohn Company | Crystallization and structure determination of staphylococcus aureus nad synthetase |
US6988041B2 (en) | 2000-01-31 | 2006-01-17 | Pharmacia & Upjohn Company | Crystallization and structure determination of Staphylococcus aureus NAD synthetase |
WO2002007516A3 (en) * | 2000-07-14 | 2002-06-27 | Uab Research Foundation | Uses for nad synthetase inhibitors |
WO2002007516A2 (en) * | 2000-07-14 | 2002-01-31 | The Uab Research Foundation | Uses for nad synthetase inhibitors |
US7056917B2 (en) | 2001-04-26 | 2006-06-06 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
WO2005002337A1 (en) * | 2003-04-02 | 2005-01-13 | Virtual Drug Development, Inc. | Disinfectant compositions and methods |
WO2005054198A3 (en) * | 2003-12-05 | 2005-09-15 | Univ Bath | Therapeutics use of pyridinium compounds to modulate naadp activity |
WO2005054198A2 (en) * | 2003-12-05 | 2005-06-16 | University Of Bath | Therapeutics use of pyridinium compounds to modulate naadp activity |
US8710232B2 (en) | 2004-04-22 | 2014-04-29 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives used as TAFIa inhibitors |
US7514457B2 (en) | 2005-05-31 | 2009-04-07 | Pfizer Inc. | Substituted aryloxymethyl bicyclicmethyl acetamide compounds |
WO2007005845A1 (en) * | 2005-07-01 | 2007-01-11 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
US7956220B2 (en) | 2005-07-01 | 2011-06-07 | Jenrin Discovery | MAO-B inhibitors useful for treating obesity |
US7696240B2 (en) | 2005-12-15 | 2010-04-13 | Hoffmann-La Roche Inc. | Fused pyrrole derivatives |
US8940901B2 (en) | 2010-11-11 | 2015-01-27 | Sanofi | Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives |
US8993560B2 (en) | 2011-03-11 | 2015-03-31 | Glaxo Group Limited | Compounds |
US9447074B2 (en) | 2011-03-11 | 2016-09-20 | Glaxo Group Limited | Compounds |
Also Published As
Publication number | Publication date |
---|---|
EP1047692A1 (en) | 2000-11-02 |
US6500852B1 (en) | 2002-12-31 |
AU2031799A (en) | 1999-08-02 |
EP1047692B1 (en) | 2004-07-21 |
ATE271555T1 (de) | 2004-08-15 |
JP2002509149A (ja) | 2002-03-26 |
DE69918799D1 (de) | 2004-08-26 |
CA2317439A1 (en) | 1999-07-22 |
US6727237B2 (en) | 2004-04-27 |
IL137229A0 (en) | 2001-07-24 |
US20040063758A1 (en) | 2004-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1047692B1 (en) | Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof and methods of treating bacterial and microbial infections with these inhibitors | |
EP1109805A1 (en) | Inhibitors of bacterial nad synthetase | |
Pirrung et al. | High-Throughput Catch-and-Release Synthesis of Oxazoline Hydroxamates. Structure− Activity Relationships in Novel Inhibitors of Escherichia c oli LpxC: In Vitro Enzyme Inhibition and Antibacterial Properties | |
Zhao et al. | Discovery of thiosemicarbazone derivatives as effective New Delhi metallo-β-lactamase-1 (NDM-1) inhibitors against NDM-1 producing clinical isolates | |
Lin et al. | Practical synthesis of hydroxamate-derived siderophore components by an indirect oxidation method and syntheses of a DIG− siderophore conjugate and a biotin− siderophore conjugate | |
Roosenberg II et al. | Studies and syntheses of siderophores, microbial iron chelators, and analogs as potential drug delivery agents | |
Qureshi et al. | Design, synthesis, in-silico studies and biological screening of quinazolinone analogues as potential antibacterial agents against MRSA | |
CN114230519A (zh) | 一类具有抗耐药菌活性的截短侧耳素肉桂酸酯类化合物及其合成方法和应用 | |
Yi et al. | Antibiotic resistance and drug modification: Synthesis, characterization and bioactivity of newly modified potent pleuromutilin derivatives with a substituted piperazine moiety | |
Yi et al. | Novel pyridinium cationic pleuromutilin analogues overcoming bacterial multidrug resistance | |
Granata et al. | Synthesis of a calix [4] arene derivative exposing multiple units of fucose and preliminary investigation as a potential broad-spectrum antibiofilm agent | |
Kim et al. | N (2)-Substituted D, L-Cycloserine Derivatives Synthesis and Evaluation as Alanine Racemase Inhibitors | |
Sethuvasan et al. | Synthesis, spectral characterization, crystal structure and molecular docking study of 2, 7-diaryl-1, 4-diazepan-5-ones | |
AU2003261481A1 (en) | Inhibitors of bacterial NAD synthetase | |
Gao et al. | Design, synthesis, and biological evaluation of vanillin hydroxamic acid derivatives as novel peptide deformylase inhibitors | |
Shang et al. | Antibacterial activity and pharmacokinetic profile of a promising antibacterial agent: 14-O-[(4-Amino-6-hydroxy-pyrimidine-2-yl) thioacetyl] mutilin | |
Sachdevaa et al. | Synthesis, evaluation and in silico studies of 1, 8-naphthyridine derivatives against antimicrobial activity | |
JP4102303B2 (ja) | 細菌性感染を治療又は予防するための方法及び組成物 | |
Rahmania et al. | In silico and in vitro assay of Hexagamavunon-6 analogs, Dibenzilyden-N-Methyl-4-piperidone as antibacterial agents | |
CN113372296A (zh) | 用于抑制多重耐药的金黄色葡萄球菌的硒啉类化合物及用途 | |
US20050251345A1 (en) | Small molecules and a pharmacophore model for inhibition of anthrax lethal factor | |
e Sana et al. | Syntheses and antimicrobial activities of amide derivatives of 4-[(2-isopropyl-5-methylcyclohexyl) oxo]-4-oxobutanoic acid | |
Rababa et al. | Synthesis, biological activity and DFT studies of 1, 3, 4-oxadiazole ring in combination with pyridinium salt | |
EP3535242B1 (en) | Dna primase and gyrase inhibitors | |
Sargsyan et al. | The Synthesis and in vitro Study of 9-fluorenylmethoxycarbonyl Protected Non-Protein Amino Acids Antimicrobial Activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 20317/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 137229 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2317439 Country of ref document: CA Ref country code: CA Ref document number: 2317439 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 540138 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999900821 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999900821 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999900821 Country of ref document: EP |